Nanotherapeutic Strategies for MASLD: From Pathological Mechanisms to Targeted Delivery Systems Authors: Na Li, Dongqi Zhou, Fanghang Ye, Fei Yu, Liyuan Hao, Shenghao Li, Qing Peng, Jiali Deng, Xiaoyu Hu Published: 2026 ABSTRACT AbstractMetabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive metabolic liver disorder driven by hepatic lipid overload, oxidative stress, mitochondrial dysfunction, innate immune activation, insulin resistance, gut–liver axis dysregulation, and liver fibrosis. These interconnected pathological processes involve hepatocyte injury, macrophage-mediated inflammation, liver sinusoidal endothelial cell dysfunction, hepatic stellate cell activation, and extracellular matrix deposition. However, conventional therapeutic agents are often limited by poor solubility, insufficient stability, low intrahepatic exposure, nonspecific distribution, and inadequate target-cell selectivity. Nanoparticle-based delivery systems may overcome these limitations by improving drug stability, hepatic accumulation, controlled release, and cell-specific delivery. This review summarizes recent advances in nanotherapeutic strategies for MASLD from three complementary perspectives: intervention in key pathological processes, cell-specific delivery to major hepatic cell populations, and the design characteristics of different nanoplatforms. We discuss nanodelivery strategies targeting lipid metabolic dysfunction, oxidative injury, inflammation, insulin resistance, gut–liver axis dysfunction, and fibrogenesis, as well as delivery approaches directed at hepatocytes, hepatic stellate cells, liver macrophages, and liver sinusoidal endothelial cells. Multicellular co-delivery strategies for modulating pathological crosstalk are also considered. In addition, we compare the advantages and limitations of inorganic nanoparticles, polymeric nanoparticles, liposomes and other lipid-based nanosystems, and bio-derived or biomimetic nanocarriers. Particular attention is given to how carrier composition, physicochemical properties, surface functionalization, and release behavior can be matched with therapeutic cargoes, target cells, and pathological processes. Although these platforms provide opportunities for multi-process and cell-specific intervention in MASLD, most evidence remains preclinical. Major barriers to clinical translation include long-term safety, controllable biodistribution, differences between experimental models and human disease, scalable manufacturing, batch-to-batch consistency, and standardized quality evaluation. Addressing these issues during nanoplatform design and assessment will be essential for translating targeted nanodelivery systems into clinically applicable therapies for MASLD.Keywords: metabolic dysfunction-associated steatotic liver disease, nanomedicine, lipid metabolism, oxidative stress, hepatic fibrosis, gut–liver axis Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) was formally adopted in 2023 by an international expert consensus to replace the previous term “non-alcoholic fatty liver disease” (NAFLD).1 This new nomenclature emphasizes the central role of metabolic dysfunction in disease onset and progression, avoids the limitation of defining the disease by the exclusionary term “non-alcoholic,” and more accurately reflects its etiological basis. According to the latest consensus, MASLD is defined as steatotic liver disease (SLD) occurring in individuals with one or more cardiometabolic risk factors, such as obesity, type 2 diabetes, hypertension, or dyslipidemia, in the absence of harmful alcohol consumption.2 MASLD encompasses a continuous pathological spectrum ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH, previously termed NASH), advanced fibrosis, and cirrhosis.3 As one of the most common chronic liver diseases worldwide, the incidence and prevalence of MASLD have continued to increase globally in recent years, making it a major public health challenge and imposing substantial social and economic burdens. Epidemiological data indicate that MASLD currently affects approximately 38% of adults and 7%–14% of children and adolescents, and this proportion is projected to exceed 55% by 2040.4,5 Its prevalence is markedly higher among individuals with metabolic abnormalities, with MASLD present in approximately 60%–70% of patients with type 2 diabetes and 70%–80% of individuals with obesity.6 In addition, with the global rise in metabolic syndrome, the prevalence of MASLD has shown a sustained upward trend in regions such as Asia, the Middle East, and Latin America.7 At present, the management of MASLD still mainly relies on lifestyle interventions, including dietary modification, increased physical activity, and weight management, supplemented by pharmacological treatment targeting metabolic abnormalities.8–10 Metabolic bariatric surgery may be considered for patients who do not respond to conventional interventions and meet the relevant indications.11 Despite recent advances in pharmacotherapy, substantial unmet clinical needs persist in the management of MASLD. Currently, disease-specific therapies are largely confined to selected patients with non-cirrhotic MASH, while those with cirrhosis, decompensated liver disease, or patients outside current treatment indications have limited options.2,12 Treatment responses vary considerably, and further data are required on the durability of histological improvements, predictive biomarkers, and long-term safety profiles.13,14 The frequent co-occurrence of obesity, type 2 diabetes, dyslipidemia, cardiovascular disease, and other cardiometabolic conditions adds further complexity to long-term management.15 As the disease progresses, some patients may develop end-stage liver disease and ultimately require liver transplantation for survival.16 The development and progression of MASLD involve multiple complex pathological processes, including dysregulated lipid metabolism, insulin resistance, oxidative stress, inflammatory responses, and liver fibrosis, which are mechanistically interconnected.17 It is now widely accepted that the onset of MASLD results from the combined effects of multiple factors.18 Abnormal lipid accumulation in hepatocytes can induce lipotoxicity and promote the development and progression of MASLD or MASH through several mechanisms, including endoplasmic reticulum stress, oxidative stress, organelle dysfunction, and ferroptosis.19 Meanwhile, damage-associated molecular patterns (DAMPs) released from injured hepatocytes can activate the hepatic innate immune system, promoting the release of inflammatory cytokines by Kupffer cells and amplifying hepatic inflammation. In addition, persistent inflammatory stimulation can activate hepatic stellate cells (HSCs), thereby promoting extracellular matrix deposition and driving the development of liver fibrosis.20–22 Therefore, therapeutic strategies targeting distinct pathological processes and key cellular populations involved in MASLD are of great significance for improving disease prognosis. In recent years, the emergence of nanomedicine has provided new opportunities to overcome the limitations of conventional therapies, with the central concept being the use of the unique physicochemical properties of NPs to achieve precise drug delivery.23 Compared with conventional formulations, nanodelivery systems can not only improve drug stability and prolong circulation time but also enable selective accumulation in specific tissues or cells through passive targeting, such as the enhanced permeability and retention (EPR) effect, or active targeting mediated by ligand–receptor recognition.24,25 Owing to its abundant blood perfusion and unique sinusoidal capillary architecture, the liver tends to exhibit substantial accumulation of NPs after their entry into the systemic circulation. Studies have shown that, during systemic circulation, most NPs are ultimately distributed predominantly in the liver, with hepatic accumulation reaching up to approximately 99% of the total administered dose.26 This pronounced liver-preferential distribution has been widely observed across different animal models and various NP platforms and appears to be largely independent of variations in physicochemical parameters, including NP size, shape, surface chemistry, and material composition.27 Based on this property, nanodelivery systems are considered to have considerable potential for directing therapeutics to hepatic parenchymal or non-parenchymal cells. Nevertheless, preferential hepatic accumulation does not necessarily ensure efficient delivery to therapeutically relevant hepatic cell populations. Moreover, pathological changes during MASLD progression, including sinusoidal capillarization and extracellular matrix deposition, may further restrict nanoparticle penetration and alter intrahepatic distribution. In addition, important translational challenges remain, particularly with respect to targeting efficiency in vivo, long-term safety, off-target accumulation, and manufacturing scalability, including reproducibility, batch-to-batch consistency, and standardized quality control. Accordingly, this narrative review is organized around three complementary and interconnected dimensions: pathological-process-oriented intervention, cell-specific hepatic delivery, and nanoplatform design. These dimensions represent different but closely related aspects of the same therapeutic framework rather than independent or mutually exclusive classification systems. As illustrated in Figure 1, the pathological-process-oriented section identifies the major disease mechanisms that require therapeutic modulation, including dysregulated lipid metabolism, oxidative stress and mitochondrial dysfunction, inflammation and innate immune activation, insulin resistance, gut–liver axis dysregulation, and fibrosis. The cell-specific delivery section then focuses on the major hepatic cell populations involved in these processes, including hepatocytes, Kupffer cells and other liver macrophages, hepatic stellate cells, and liver sinusoidal endothelial cells. The nanoplatform section discusses how therapeutic cargoes can be matched with appropriate carrier materials and design parameters to achieve delivery to these pathological and cellular targets. Because MASLD is driven by multicellular crosstalk and overlapping pathological mechanisms, many nanotherapeutic systems cannot be assigned exclusively to a single mechanism, target cell population, or material category. A multifunctional nanoplatform may, for example, simultaneously reduce hepatocellular lipotoxicity, regulate macrophage-mediated inflammation, restore sinusoidal endothelial function, and suppress hepatic stellate cell activation. Therefore, representative systems are discussed in more than one relevant context when necessary. To avoid unnecessary repetition, each system is described in greatest detail in the section most closely related to its primary therapeutic action, while its additional pathological effects, cellular targets, or platform characteristics are cross-referenced in the corresponding sections. Figure 1 provides an integrated conceptual framework linking MASLD pathogenesis and therapeutically relevant cell populations with therapeutic cargoes, nanocarrier platforms, key design factors, expected therapeutic outcomes, and major translational challenges. The subsequent figures provide more detailed summaries of the pathological mechanisms, cellular interactions, and functional characteristics of the principal nanoplatforms, whereas Table 1 summarizes representative studies according to experimental model, nanoparticle formulation, therapeutic cargo, target or mechanism, and major outcomes. Conceptual framework of nanotherapeutic strategies for metabolic dysfunction-associated steatotic liver disease. MASLD is driven by interconnected pathological processes, including dysregulated lipid metabolism, oxidative stress and mitochondrial dysfunction, inflammation and innate immune activation, insulin resistance, gut–liver axis dysregulation, and fibrosis and extracellular matrix remodeling. These processes involve multiple hepatic cell populations, particularly hepatocytes, hepatic macrophages, hepatic stellate cells, and liver sinusoidal endothelial cells, which interact through multicellular crosstalk. Rational nanotherapeutic development requires matching therapeutic cargoes with appropriate nanocarrier platforms while optimizing key design factors for hepatic targeting. Representative therapeutic cargoes include small-molecule drugs, natural products, antioxidants, anti-inflammatory and antifibrotic agents, siRNA, miRNA, mRNA, proteins, peptides, and combination therapies. Major nanocarrier platforms include inorganic nanoparticles, polymeric nanoparticles, liposomes and other lipid-based nanosystems, bio-derived or biomimetic systems, and virus-like particles. Key design factors include particle size, surface charge, material composition, targeting ligands, drug loading and release, and microenvironment responsiveness. These strategies aim to reduce hepatic steatosis, oxidative stress, and inflammation; improve insulin sensitivity and gut–liver and sinusoidal homeostasis; and reduce hepatic stellate cell activation and hepatic fibrosis. Major translational challenges include the development of disease-relevant models, biodistribution and targeting efficiency, long-term safety and clearance, scalable manufacturing, batch consistency and quality control, and regulatory evaluation. In the left panel, solid arrows indicate directional or reciprocal interactions among pathological processes and hepatic cell populations. Dashed lines in the middle panel indicate the integration of therapeutic cargoes, nanocarrier platforms, and design factors in cargo–carrier matching for hepatic targeting. The thick interpanel arrows indicate the conceptual progression from MASLD pathogenesis and hepatic cellular targets to nanotherapeutic components and major therapeutic directions. The red cross (×) indicates impaired insulin signaling. Abbreviations: MASLD, metabolic dysfunction-associated steatotic liver disease; HSCs, hepatic stellate cells; LSECs, liver sinusoidal endothelial cells; ECM, extracellular matrix; ROS, reactive oxygen species; VLPs, virus-like particles; siRNA, small interfering RNA; miRNA, microRNA; mRNA, messenger RNA. Table 1Nanoparticle-Based Therapeutic Strategies for MASLD and Their Potential MechanismsCategoryNanosystem/MaterialLoaded Drug or Functional ComponentModelMain EffectsPotential MechanismsInorganic nanoparticlesCerium oxide nanoparticles (CeO2 NPs).28–30CeO2 with intrinsic antioxidant enzyme-like activityMAFLD/MASH animal modelsAlleviate hepatic steatosis, inflammation, oxidative stress, and fibrosisScavenges ROS through antioxidant enzyme-like activity, restores redox homeostasis, and suppresses inflammation and lipid accumulationLiver-targeted selenium nanoparticles.31–33GA-MSe@AR, LCS-SeNPs, biomimetic selenium nanocompositesMAFLD/MASH modelsImprove hepatic lipid deposition, oxidative stress, intestinal barrier injury, and iron homeostasis imbalanceExert antioxidant and lipid-lowering effects and regulate the intestinal barrier, gut microbiota, lipophagy, and lipid/iron homeostasisChitosan-coated selenium nanoparticles (CS-SeNPs).34Elemental seleniumFFA-induced steatotic HepG2 cell model; HFD-induced mouse model of NAFLDAmeliorated hepatic steatosis, improved liver function, and attenuated oxidative stress and inflammationEnhanced lipophagy and upregulated PPARα, CPT-1A, and PGC-1α, thereby promoting fatty acid oxidationZinc oxide nanoparticles (Lut/ZnONPs).35LuteolinDiabetes-associated MAFLD rat modelImprove hepatic steatosis, insulin resistance, and liver injuryModulate the PI3K/AKT/FoxO1 pathway, attenuate oxidative stress, and improve metabolic disordersUnloaded zinc oxide nanoparticles (ZnO NPs.)36Intrinsic bioactivity of ZnO nanoparticlesHFD-induced mouse model of NAFLDAttenuated hepatic steatosis and peripheral insulin resistanceActivated hepatic SIRT1–LKB1–AMPK signaling and promoted the cytoplasmic retention of SREBP-1c, thereby suppressing de novo lipogenesisGold nanoparticles (ESC-ABD-AuNPs).37Esculentin-2CHa fusion protein-modified Au NPsHFD-fed obese mouse modelAmeliorate MAFLD-associated liver injuryAttenuate hepatic steatosis progression through anti-inflammatory, antioxidant, and hepatoprotective effectsFullerene derivative (QF70).38Carboxyl fullerene derivativePA/OA-induced hepatocyte lipid droplet model; HFHC/HFD-induced MASLD mouse model; ob/ob mouse model; cynomolgus monkey MASLD modelInhibit hepatocellular lipid droplet accumulation, alleviate hepatic steatosis, inflammation, and fibrosis, and improve obesity-related metabolic disorders and insulin resistanceDirectly binds to the lipid droplet membrane protein PLIN2 and promotes its lysosome-dependent degradation, thereby reducing lipid droplet stability and improving lipid metabolic dysfunctionCopper-based nanosystem.39Resveratrol and ultrasmall CuNPsOA-induced HepG2 cell modelImprove lipid metabolic dysfunctionEnhance targeted delivery through aptamer-functionalized ultrasound nanobubbles and exert antioxidant and metabolic regulatory effectsPEGylated thiolated hollow mesoporous silica nanoparticles (ONL@MSN).40Obeticholic acid (OCA), Liproxstatin-1, and an S-nitrosothiol-based nitric oxide donorMCD-induced mouse model of NASHAmeliorated hepatic steatosis, ferroptosis, inflammation, fibrosis, immune dysregulation, and gut microbiota dysbiosisOCA activated FXR signaling, Liproxstatin-1 inhibited lipid peroxidation and ferroptosis, and the S-nitrosothiol released nitric oxide. Together, these effects reduced the expression of α-SMA, TIMP-1/2, and collagen, thereby exerting synergistic antifibrotic effectsHollow mesoporous silica-based hydrogen nanocapsules (AB@hMSN@PEG).41Ammonia borane for sustained H2 releaseHFD-induced mouse models of obesity and early-stage MAFLD; db/db mouse models of genetic obesity, diabetes, and early-stage MAFLDAmeliorated hepatic steatosis, obesity, and diabetes and improved the hepatic metabolic profileSustained high-dose H2 release reprogrammed hepatic lipid metabolism by suppressing lipid synthesis and promoting fatty acid metabolism. It also modulated the gut microbiota and increased the abundance of Akkermansia muciniphila, thereby improving MAFLD and glucose and lipid metabolismCerium–phytic acid nanocomplexes (CePA)42Complexes formed through the coordination of phytic acid with cerium ionsHFCFG-induced mouse model of MASHReduced hepatic lipid accumulation and inflammatory responsesThe phosphate-rich CePA nanocomplexes interfered with mTOR phosphorylation at Ser2448 and suppressed the mTOR–SREBP1 lipogenic and immunoregulatory axisPolymeric nanoparticlesmPEG-PLGA nanoparticles (mPEG-PLGA).43RapamycinOA-induced HepG2 lipid deposition model; HFD-induced MAFLD mouse modelReduce hepatocellular lipid accumulation, hepatic steatosis, and liver injuryImprove hepatic lipid homeostasis by downregulating SREBP-1c-mediated de novo lipogenesis-related genes and upregulating PPARα-mediated fatty acid oxidation-related genesPLGA nanoparticles (RSV-PLGA-NPs).44ResveratrolIn vitro HepG2 lipid deposition modelImprove RSV stability, solubility, and bioactivity and reduce intracellular lipid accumulationInhibit lipogenesis, promote lipolysis, and reduce hepatocyte proliferationGalactose-modified oxidized starch–lysozyme nanocarriers (Gal-OSL/Res).45ResveratrolFFA-induced steatotic HepG2 cell model; HFD-induced mouse model of NAFLDPromoted ASGPR-mediated hepatocyte uptake, activated the AMPK/SIRT1 pathway, inhibited SREBP-1c/FAS-mediated lipogenesis, and reduced IRS-1 phosphorylation at Ser307Promoted ASGPR-mediated hepatocyte uptake, activated the AMPK/SIRT1 pathway, inhibited SREBP-1c/FAS-mediated lipogenesis, and reduced IRS-1 phosphorylation at Ser307Chitosan- and mannose-modified PLGA–PEG nanoparticles (ICA-NPs).46IcariinPA/OA-induced HepG2 cell model of NAFLD; HFD-induced mouse model of NAFLDReduced hepatic lipid accumulation and oxidative stress and improved obesity, dyslipidemia, and liver functionEnhanced oral absorption and mannose receptor-mediated hepatocyte uptake, promoted Nrf2 nuclear translocation, scavenged ROS, and increased SOD activity while reducing MDA, TNF-α, and IL-6 levelsGalactose-modified PLGA–PEG nanoparticles (EC@PLGA-PEG-GAL NPs).47EpicatechinPA-induced lipotoxicity model in HepG2 cells; HFD-induced mouse model of MASLDAttenuated hepatic steatosis and inflammation and improved obesity, insulin resistance, and liver functionPromoted ASGPR-mediated targeted hepatocyte uptake, activated AMPK, inhibited mTOR, and restored autophagic flux; it also reduced mitochondrial ROS, restored mitochondrial membrane potential, and promoted mitochondrial biogenesisAlbumin–ginsenoside compound K nanoparticles (nabCK)48Ginsenoside compound K (CK)3T3-L1 adipocytes and steatotic HepG2 cells; HFD-induced mouse model of NAFLDInhibited hepatic steatosis and fibrosis and alleviated cardiac lipotoxicityAlbumin facilitated liver-selective delivery; mTORC1 inhibition reduced lipid uptake, storage, and synthesis while promoting lipid exportChitosan-modified lipid–polymer hybrid nanoparticles (CS-LPNs; PLGA polymeric core/soybean lecithin and DSPE–PEG2000 lipid shell/chitosan surface layer).49SilymarinFat emulsion-induced lipid accumulation model in HepG2 cells; HFD-fed PNPLA3 I148M transgenic mouse model of NAFLDEnhanced oral bioavailability and reduced serum TG and liver enzyme levels and hepatic steatosisThe PLGA core and lipid shell improved the encapsulation, solubility, and stability of silymarin; chitosan enhanced intestinal mucoadhesion, epithelial uptake, and intestinal absorption and increased uptake by steatotic hepatocytes, thereby enhancing the lipid-lowering and hepatoprotective effects of silymarinDOTAP-modified PEG-b-PLA cationic nanoparticles (NP-NAR).50NaringeninHFD-induced mouse model of MASLDReduced hepatic lipid accumulation, oxidative stress, and inflammation and improved obesity, dyslipidemia, and insulin resistanceActivated PPAR signaling and suppressed CD36, ACC, and FASN expression, thereby promoting fatty acid oxidation and reducing lipid uptake and synthesis; it also upregulated INSR expression and modulated the gut microbiota and short-chain fatty acid metabolismProhibitin-binding peptide-modified PLGA nanoparticles (PBP-NPs).51Heme or cobalt protoporphyrin (HO-1 inducers)FFA-induced steatotic AML12 hepatocyte model; HFD-induced mouse model of obesity/T2DM; HFHFD-induced mouse model of NASHAmeliorated obesity, insulin resistance, hepatic steatosis, inflammation, and fibrosisAchieved prohibitin-mediated dual targeting of adipose tissue and steatotic liver, induced HO-1 expression, and promoted adipose tissue browning and mitochondrial biogenesis; it also downregulated SREBP-1c and FASN, promoted M2 macrophage polarization, and reduced lipid accumulation, inflammatory cytokine production, and HSC activationPLGA nanoparticles (R406-PLGA).52Spleen tyrosine kinase inhibitor R406LPS/IFN-γ-induced RAW264.7 macrophages and bone marrow-derived M1 macrophages; MCD diet-induced mouse model of NASHAttenuated hepatic steatosis, inflammation, and fibrosis and reduced aminotransferase and circulating lipid levelsInhibited macrophage SYK/CARD9 signaling and M1 inflammatory responses and reduced CCL2, TNF-α, IL-6, and iNOS expression; it also suppressed HSC activation and promoted PGC-1α/PRDM16/UCP1-mediated lipid oxidationPLGA nanoparticles (Rimo-NPs).53RimonabantHFD-induced obese mouse model with hepatic steatosis and insulin resistanceAlleviate hepatic steatosis, liver injury, and hypertriglyceridemia and improve insulin sensitivityAchieve peripheral delivery of rimonabant through PLGA nanoencapsulation, block hepatic CB1R, promote hepatocyte fatty acid oxidation, and reduce centrally mediated adverse effectsPolyurethane nanoparticles (FNB-PU).54FenofibrateOA-induced HepG2 lipid deposition model; MCD diet-induced MAFLD mouse modelReduce TG levels in cells and mouse liverSustain fenofibrate release via polyurethane nanoparticles, improve drug absorption, and enhance PPARα-mediated lipid-lowering effectsLactosylated albumin nanoparticles (CEL-Lac-BSA).55CelastrolHFD-induced MAFLD mouse modelReduce hepatic lipid deposition and improve liver function and insulin sensitivityEnhance hepatic delivery via lactosylated albumin and regulate AMPK/SIRT1/FASN/SREBP-1c-related lipid metabolic pathwaysGalactose- and TPP-functionalized dextran nanoparticles (CsA@Dex-Gal/TPP)56Cyclosporine A (CsA)PA-treated HepG2 cells; HFD-induced mouse model of NAFLDRestored mitochondrial function and mitophagy and improved glucose and lipid metabolism and hepatic steatosisSequentially achieved hepatocyte targeting, lysosomal escape, and mitochondrial targeting; inhibited mPTP opening, maintained mitochondrial membrane potential, and reduced ROS productionSelf-assembled PEG-b-poly(cysteine) antioxidant nanoparticles [NanoCys(Bu)]ss.57Protected L-cysteine unitsCDAHFD-induced mouse model of early-stage MASHReduced hepatic lipid accumulation, oxidative stress, inflammation, and fibrosisUnderwent degradation by endogenous enzymes to release cysteine, whose thiol groups scavenged ROS and maintained redox homeostasisAEAA-modified PLGA–PEG/G0-C14 nanoparticles (NP-AEAA).58siRNAs targeting IL11 or IL11RA1Primary activated HSCs; HFCMCD- and HFHC diet-induced mouse models of NASHInhibited HSC activation and attenuated hepatic steatosis, inflammation, and fibrosisPreferentially accumulated in activated HSCs and inhibited IL-11/ERK signaling, HSC transdifferentiation, and fibrotic ECM remodelingEnzyme-responsive self-assembled polymeric micelles based on PEG-b-poly(OEA acrylate) (NanoOEA).59Oleoylethanolamide (OEA) covalently conjugated through ester bondsCDAHFD-induced mouse model of early-stage MASHReduced aminotransferase levels, hepatic lipid accumulation, and inflammation and improved tolerabilityEnabled sustained hepatic delivery and enzyme-triggered OEA release, thereby increasing PPAR-α expression, enhancing lipolysis, and suppressing inflammatory signalingPVA-coated PLA nanoparticles encapsulating PEI/siRNA complexes (CD98 siRNA-NPs).60CD98 siRNALPS-stimulated inflammatory model in HepG2 cells; HFD-induced mouse model of NAFLDReduced hepatic lipid vacuolization and triglyceride accumulation, decreased ALT and inflammatory cytokine levels, and attenuated hepatic inflammation and fibrosisFollowing uptake by hepatocytes and macrophage-like cells, the nanoparticles provided sustained siRNA release and downregulated CD98 expression, thereby suppressing proinflammatory signaling involving IL-1β, IFN-γ, COX-2, TNF-α, and IL-6 and inhibiting the progression of lipid accumulation-associated inflammation and fibrosisRedox-responsive heparin–PGEA core–shell nanocomplexes (Hep@PGEA; disulfide-crosslinked heparin core/ethanolamine-modified poly(glycidyl methacrylate) cationic shell).61MST1-encoding plasmid (HCP/MST1) or plasmid encoding MST1-targeting siRNA (HCP/siMST1)PA-induced steatotic AML-12 cell model; HFD-induced mouse model of NAFLDImproved insulin sensitivity and reduced liver injury and hepatic lipid accumulationDelivered MST1 to the diseased liver and activated the AMPK/SREBP-1c axis, whereas MST1 knockdown produced the opposite effectsStyrene–maleic acid copolymer nanomicelles (SMA/CORM2).62Carbon monoxide-releasing molecule 2 (CORM2)FFA-treated hepatocytes; HF-MCD diet-induced mouse model of MAFLDAmeliorated steatohepatitis, inflammation, and fibrosisProvided sustained CO release and inhibited HIF-1α, subsequently suppressing M1 macrophage polarization, NLRP3 inflammasome activation, and TGF-β signalingGalactose- and TPP-dual-functionalized whey protein isolate nanocarriers (AST@TPP-WPI-Gal).63AstaxanthinSteatotic HepG2 cells; HFD-induced mouse model of NAFLDAmeliorated dyslipidemia, liver dysfunction, oxidative stress, and hepatic lipid accumulationASGPR-mediated hepatocyte uptake and TPP-mediated mitochondrial targeting enhanced the antioxidant and antilipogenic activities of astaxanthinGlycogen-based nanoparticles (Gly–LA–Lac/Res NPs).64ResveratrolPA-induced HepG2 lipotoxicity model; HFD-induced MAFLD mouse modelReduce hepatic lipid accumulation, oxidative stress, and liver injuryAchieve liver-targeted and redox-responsive release of resveratrol and suppress TLR4/NF-κB inflammatory signalingPolymeric metformin-cell-penetrating peptide hybrid nanoparticles (CDPIA).65IL-22 geneHFD-induced MAFLD mouse modelAlleviate hepatic steatosis and improve insulin sensitivity and metabolic syndromeDeliver the IL-22 gene to the liver, activate STAT3/Erk1/2 and Nrf2/SOD1 signaling, and regulate lipid metabolism-related gene expressionGA-modified chitooligosaccharide-N-acetylcysteine nanoparticles (GCNp-Cur NPs).66CurcuminMAFLD cell and mouse modelsAttenuate hepatic lipid accumulation and oxidative damage and delay MAFLD progressionMediate hepatocyte-targeted delivery through GA-R, regulate the GPX4/GSH pathway, and inhibit lipid peroxidation, Fe2⁺ accumulation, and ferroptosisLow-molecular-weight chitosan-bilirubin nanoparticles (LMWC-BRNPs).67BilirubinMCD diet-induced MASH mouse modelAlleviate hepatic oxidative stress, inflammation, fat deposition, and fibrosisAre taken up by hepatic macrophages and HSCs, regulate hepatic immune responses, and activate PPARα-related lipid metabolismPEGylated bilirubin self-assembled nanoparticles (PEG-BR; mPEG2000–bilirubin conjugates).68BilirubinHFD-fed mouse model of NAFLDReduced hepatic TG content, de novo lipogenesis, liver injury markers, and VLDL-ApoB100 levels while increasing β-hydroxybutyrate levelsBilirubin may act as a PPARα ligand and upregulate ACOX1, CYP4A12, and FATP1/2, thereby promoting fatty acid uptake, β-oxidation, and ketogenesis; it also suppressed FAS- and SCD1-mediated lipogenesis, ultimately ameliorating hepatic steatosisHyaluronic acid-bilirubin nanoparticles (HABNs).69Hyaluronic acid-bilirubin conjugateCD-HFD-induced MASH fibrosis mouse model; activated HSCsTarget activated HSCs, inhibit HSC activation, proliferation, and collagen production, and attenuate MASH-associated liver fibrosisMediate HSC-targeted uptake via CD44 and inhibit HSC activation and collagen deposition through antioxidant effectsRedox nanoparticles (RNPs).70Nitroxide radical-containing redox polymerCDAA diet-induced fibrotic MASH mouse modelReduce hepatic ROS levels, inflammatory cell infiltration, and MASH-associated liver fibrosisDisassemble after oral administration and reach the liver, where they scavenge ROS and suppress inflammation and HSC activationGalactose-modified five-component cationic lipid nanoparticles (Gal-LNP-RSV; MC3/DSPC/cholesterol/DMG-PEG2000/Gal-PEG2000-DSPE).71Resveratrol (RSV)OA/PA-induced steatotic HepG2 cell model; HFD-induced mouse model of NAFLDReduced lipid accumulation in hepatocytes and liver tissues, improved serum lipid profiles and ALT/AST levels, and attenuated oxidative stressGalactose specifically bound to hepatocyte ASGPR, promoting receptor-mediated endocytosis and targeted hepatic accumulation and enhancing the intracellular delivery efficiency of RSV, thereby regulating lipid metabolism and restoring redox homeostasisNASH-targeting aptamer-modified, ROS-responsive, and ultrasound-activated lipid nanobubbles (Apt-DTP-NBs@RSV@OCA; DSPE-TK-PEG lipid shell/C3F8 gas core).72Resveratrol (RSV) and obeticholic acid (OCA)FFA-induced HepG2 cell model of NASH; MCD diet-induced mouse model of NASHReduced lipid accumulation and ROS levels, modulated inflammatory cytokine expression and oxidative stress, and enhanced targeted drug accumulation in the liverThe aptamer facilitated selective targeting of NASH cells, whereas ultrasound exposure and elevated ROS levels triggered drug release; RSV activated SIRT1 and enhanced OCA-mediated FXR/SHP–FoxO1 signaling, thereby improving lipid metabolism, oxidative stress, and inflammationLiposomes and lipid-based nanosystemsBaicalin nanoliposomes (BA-NL).73BaicalinMCD diet-induced MAFLD/MASH-like mouse modelAlleviate hepatic steatosis, inflammatory cell infiltration, hepatocyte apoptosis, and fibrosisDeliver baicalin via liposomes and inhibit the TLR4 signaling cascade and pro-inflammatory cytokine productionLactobionic acid-modified poly(2-(dimethylamino)ethyl methacrylate) nanoparticles (Lac-PDMAEMA).74miR-146b mimicPA-induced lipid accumulation models in HepG2 and AML12 cells; MCD diet-induced mouse model of NAFLDReduced hepatocellular lipid accumulation and hepatic inflammation and decreased ALT, AST, and proinflammatory cytokine levelsLactobionic acid enabled targeted delivery through hepatocyte ASGPR-mediated endocytosis; miR-146b downregulated MyD88 and IRAK1, suppressed TLR4-associated inflammatory signaling, and reduced PPARγ and C/EBPα expression, thereby inhibiting lipid droplet formation and inflammatory responsesPEG/PEI-crosslinked nanogels (HT/NG0.1 and HT/NG0.5).75HydroxytyrosolOA/PA-induced steatotic HepG2/C3A cell modelReduced intracellular triglyceride accumulation and lipid deposition, attenuated free fatty acid-induced lipotoxicity, and restored cell viabilityImproved the stability and intracellular delivery efficiency of hydroxytyrosolFenofibrate nanoliposomes (FNB-Nanolipo).76FenofibrateMCD diet-induced MAFLD mouse modelReduce hepatic lipid deposition and improve MAFLD pathological changesImprove fenofibrate delivery and bioavailability through nanoliposomes and enhance PPARα-mediated regulation of lipid metabolismROS-responsive OVE/DSPE-PEG nanoparticles (FNB-NP).77FenofibrateMCD diet-induced mouse model of NAFLDIncreased the in vivo exposure of fenofibrate and reduced hepatic lipid accumulation, oxidative stress, and liver injuryExerted therapeutic effects through ROS-responsive drug release, ROS scavenging by the vitamin E-derived moiety, and PPARα activationROS- and ultrasound-dual-responsive lipid nanocarriers (RP-LipoTK; DSPE-TK-PEG-modified lipid shell).78Resmetirom and perfluorohexane (PFH)HFD-induced mouse model of MASHEnhanced drug accumulation and deep tissue penetration in the fibrotic liver, attenuated hepatic steatosis, inflammation, oxidative stress, and fibrosis, and improved lipid metabolismElevated ROS levels in the MASH microenvironment cleaved the thioketal bonds and induced PEG shedding, simultaneously scavenging ROS and enhancing hepatocyte uptake; ultrasound induced the liquid-to-gas phase transition and cavitation of PFH, facilitating rapid resmetirom release and penetration through the dense ECM and subsequently activating THR-β signalingTPP-modified pH-responsive polymer–cationic peptide nanoparticles (mito-NP).79circRNA SCARPalmitate-induced human hepatic fibroblast model; HFD-induced mouse model of NASH/cirrhosisReduced oxidative stress and inflammation, inhibited fibroblast activation, hepatic fibrosis, and macrophage infiltration, and improved insulin resistanceEnabled mitochondria-targeted delivery of circRNA SCAR, which bound to ATP5B and disrupted the CypD–mPTP interaction, thereby inhibiting mPTP opening and mitochondrial ROS releaseHepatocyte-targeted nanoliposomes (Glipo-siRubi).80Rubicon siRNAHepa1-6 cell lipid deposition model; WD-induced MAFLD mouse modelReduce hepatic lipid accumulation and liver injury, and improve histopathological changes and insulin resistanceGalactose modification promotes ASGPR-mediated hepatocyte uptake, silences Rubicon expression, restores autophagic flux, and reduces ER stresssgRubicon-LNP.81CRISPR-Cas9 targeting RubiconFFA-induced hepatocyte model; HFD-induced MAFLD mouse modelAlleviate hepatic steatosis and improve dyslipidemia, glucose tolerance, and insulin sensitivityMediate hepatic delivery of CRISPR-Cas9 targeting Rubicon via LNPs, reduce CD36 expression, regulate glycerophospholipid metabolism, and restore autophagic activityDNNA-COP-NA-based LNPs (SLB/siHIF1α-LNPs)82siHIF1α and silybinHFD- and CCl4-induced MASLD mouse modelAlleviate hepatic inflammation, hypoxia-related injury, and fibrosis progressionEnhance hepatocyte-targeted delivery through the ApoE-LDLR/VLDLR axis, silence HIF-1α, and synergistically block the HIF-1α/NF-κB/TGF-β pathway with SLB, thereby reducing HSC activation and immune imbalanceVitamin E-functionalized mRNA-LNP (Def-LNP@mRNA^TCPTP).83TCPTP-encoding mRNAPreclinical models of MAFLD and MAFLD-associated HCCImprove steatohepatitis, remodel hepatic metabolic and immune microenvironments, and enhance responses of MAFLD-associated HCC to cancer vaccines and immune checkpoint blockadeDef-LNP reduces LNP-induced hepatic oxidative stress and promotes hepatocyte mRNA expression; TCPTP expression suppresses hepatocyte STAT signaling and induces metabolic reprogramming and immune microenvironment remodelingHepatocyte-targeted AA3G lipid nanoparticles(mIL11-scFv@AA3G)84mRNA encoding an IL-11-neutralizing single-chain variable fragment (scFv) antibodyHFHC diet-induced mouse models of early-stage MASH and fibrotic MASHReversed steatohepatitis, prevented fibrosis progression, and promoted the resolution of established inflammation and fibrosisInduced sustained and liver-specific expression of the IL-11-neutralizing scFv and inhibited IL-11 signaling in hepatocytes and HSCsAnti-CD5 antibody-targeted lipid nanoparticles (CD5-tLNPs).85mRNA encoding an anti-FAP chimeric antigen receptor (CAR)FAT-MASH mouse model induced by a Western diet, sugar-supplemented drinking water, and low-dose CCl4Markedly reduced hepatic fibrosis and inflammation and restored liver homeostasisTransiently generated anti-FAP CAR T cells in vivo, which eliminated FAP-positive profibrotic HSCs and subsequently restored the functional states of immune cells, endothelial cells, and hepatocytesAll-trans retinoic acid-modified fibrosis-targeting lipid nanoparticles (ATRA-LNPs; FORT system).86mRNA encoding a relaxin–collagen-binding domain fusion protein (mRLN-PLGF1) or an IL-10–collagen-binding domain fusion protein (mIL-10-PLGF1)CCl4-induced mouse model of liver fibrosis; MCD diet-induced mouse model of MASH; CDHFD-induced hamster model of MASHAttenuated hepatic steatosis, inflammation, liver injury, and fibrosis and increased the retention of therapeutic proteins within fibrotic liver tissuesATRA promoted uptake by activated HSCs and endosomal escape through RBP4/STRA6; the collagen-binding domain anchored the therapeutic proteins within the fibrotic ECM, thereby suppressing TGF-β/α-SMA signaling and inflammatory responsesMannose-modified stable nucleic acid lipid particles (mLNP-siHMGB1).87HMGB1 siRNA combined with docosahexaenoic acid (DHA)RAW264.7 macrophages; HFD-induced mouse model of NASHAttenuated lobular inflammation and macrovesicular steatosis and restored liver functionAchieved mannose receptor-mediated macrophage targeting and HMGB1 silencing and promoted anti-inflammatory M2 macrophage polarizationLipid nanoparticles composed of DLin-MC3-DMA, DSPC, cholesterol, and DMG-PEG2000 (mLNPs).88miR-26b-3p and miR-26b-5p mimicsWestern diet-induced MASH model in Apoe−/−/Mir26b-deficient mice; human precision-cut liver slice modelReduced hepatic cholesterol and lipid accumulation and suppressed inflammation-associated kinase activity; decreased TNF, CCL2, and CXCL1 secretion in human liver slicesRestored miR-26b expression and downregulated MSR1, thereby reducing macrophage lipid uptake; it also suppressed inflammatory signaling involving JNK, MAPK, and ERK and reduced Tgfb expressionDOTAP-assisted PEG–PLA cationic nanoparticles (NP-BC).89β-CaroteneHFD-induced mouse model of MASLDAmeliorated insulin resistance, inflammation, hepatic steatosis, and gut microbiota dysbiosisInhibited the PI3K/AKT/mTOR pathway and PPARγ expression and improved gut microbiota compositionSolid lipid nanoparticles (BBR-SLNs).90Berberinedb/db mouse model of diabetes-associated hepatic steatosisPromote hepatic berberine accumulation, reduce hepatic TG content and lipid droplet accumulation, and alleviate hepatic steatosisIncrease intrahepatic berberine exposure, downregulate SREBP1c, FAS, and SCD1, and upregulate CPT1, thereby inhibiting lipogenesis and promoting lipid breakdownLipid nanocapsules (EXE-RM-LNCs).91 /semaglutide-loaded lipid nanocapsules.92Exenatide (a GLP-1 receptor agonist)/semaglutideHFD-fed foz/foz mouse model of early-stage MASH/Western diet-induced mouse model of MASLDImproved glucose homeostasis and insulin resistance, delayed MAFLD/MASH progression, and partially attenuated hepatic steatosis and inflammationOrally administered lipid nanocapsules promoted endogenous GLP-1 secretion and increased the delivery efficiency and systemic exposure of GLP-1 receptor agonists, thereby exerting metabolic regulatory and anti-inflammatory effectsBile acid/fatty acid-integrated nanoemulsomes (BA/FA-NES).93Lovastatin (LVN)Experimental MAFLD rat modelImprove blood lipid profiles, liver function, and hepatic histopathology in experimental MAFLD ratsBile acid/fatty acid-integrated design improves NES stability, intestinal permeation, and liver-targeted delivery of lovastatinNanostructured lipid carriers (NLCs; glyceryl monostearate, phosphatidylcholine, phosphatidylserine, and α-tocopherol).94Active vitamin D3 [1,25(OH)2D3]LPS-stimulated Caco-2 intestinal epithelial cell model and Caco-2/RAW264.7 co-culture model; MCD diet-induced mouse model of NASHImproved intestinal barrier permeability and attenuated hepatic steatosis, inflammation, injury, and fibrosisUpregulated intestinal ZO-1 and claudin-1 to maintain barrier integrity and inhibited macrophage NF-κB activation and hepatic IL-6 and IL-1β expression, thereby ameliorating gut–liver axis inflammationSurfactant-stabilized basil essential oil-in-water nanoemulsion (BNO; Cremophor RH40/Tween 80 and propylene glycol; particle size, approximately 15.42 nm).95Basil essential oil, primarily containing linalool, eucalyptol, and eugenolHigh-fructose–saturated-fat–choline-deficient diet-induced rat model of NASHReduced hepatic lipid accumulation, ameliorated liver and colonic tissue injury, and modulated gut microbiota dysbiosisModulated the gut microbiota and reduced the Firmicutes/Bacteroidetes ratio and plasma LCN2 levels, potentially alleviating hepatic lipid accumulation and inflammation by improving the gut–liver axisNonionic surfactant vesicles (PHYLN-NIO; Span 60/cholesterol/PEG4000).96Ethanolic extract of Phyllanthus niruri containing bioactive constituents such as polyphenols, flavonoids, and lignansHFD-induced Sprague–Dawley rat model of obesity-associated hepatic steatosisAttenuated obesity and hepatic steatosis and improved dyslipidemia, insulin resistance, oxidative stress, inflammation, and liver functionDownregulated lncRNA MALAT1 and upregulated miR-206, thereby restoring GLP-1/GLP-1R signaling; inhibited LXR-α/SREBP-1c/FASN/ACC-1-mediated lipogenesis, upregulated FXR/FOXA2/PPAR-α signaling to promote fatty acid oxidation, and reduced NF-κB, IL-6, and IL-1β levelsBio-derived and biomimetic nanosystemsM2 macrophage membrane-coated PLGA nanoparticles (O@PLGA@M).97Obeticholic acid (OCA)FFA-induced RAW264.7 and AML12 cell models; MCD diet-induced mouse model of NASHAttenuated hepatic steatosis, inflammation, fibrosis, and hepatocellular injury and ameliorated gut microbiota dysbiosisTargeted the inflamed liver through chemotaxis, promoted macrophage repolarization from the M1 to M2 phenotype, activated FXR, and modulated the gut–liver axisCD44 aptamer-modified, macrophage membrane-coated, diselenide-bridged mesoporous silica nanoparticles (MSNs@RA/LA@CM-AP).98Retinoic acid (RA) and the adrenoceptor antagonist labetalol (LA)TGF-β1-induced LX-2 cell activation model; FFA-induced steatotic HepG2 cells cocultured with sympathetic neurons; BDL-induced mouse model of liver fibrosis and HFD-induced mouse model of NAFLDAttenuated hepatic steatosis, inflammation, and fibrosis, reduced hepatic lipid and collagen deposition, and improved liver functionThe macrophage membrane reduced clearance by Kupffer cells, whereas the CD44 aptamer promoted targeting of activated HSCs; diselenide bonds were cleaved in the high-ROS microenvironment, triggering drug release while scavenging ROS; RA inhibited lipogenesis and promoted HSC quiescence, whereas LA blocked norepinephrine–adrenergic receptor signaling and disrupted the profibrotic and prosteatotic crosstalk among sympathetic neurons, HSCs, and hepatocytesPlatelet–neutrophil hybrid membrane-coated gelatin nanoparticles (PNM-G-PV).99Pioglitazone and vitamin EOA/PA-induced steatotic L02 hepatocyte model; atherogenic HFD-induced C57BL/6 mouse model of NASHAttenuated hepatic steatosis, inflammation, and liver injury and improved dyslipidemia and oxidative stressThe hybrid cell membrane conferred immune-evasive properties and enabled targeting of inflamed liver tissues; MMP-9, which was highly expressed at NASH sites, degraded the gelatin matrix and triggered drug release; pioglitazone improved insulin sensitivity, whereas vitamin E scavenged ROS, with concurrent reductions in MMP-9, TNF-α, and IL-1β levelsGalNAc-modified macrophage membrane-coated PLGA nanoparticles (GalNAc-MM@PLGA/Mel).100MelatoninOA/PA-induced steatotic AML12 hepatocyte model; HFD-induced mouse model of NAFLDReduced hepatic steatosis and inflammation and improved liver injury, dyslipidemia, and insulin resistanceThe macrophage membrane conferred immune-evasive properties, whereas GalNAc promoted hepatocyte targeting through ASGPR; the delivered melatonin reduced ROS and suppressed the IRE1/PERK/ATF6–ATF4–CHOP endoplasmic reticulum stress pathway, subsequently downregulating NF-κB signaling and TNF-α and IL-1β expressionGlycyrrhizic acid–Zn2⁺ metal–organic framework nanoparticles coated with galactose-modified erythrocyte membranes (GA-RM/GZ/PL).101Circrna_0001805-expressing plasmid and glycyrrhizic acidFFA-induced steatotic primary human hepatocyte model; HFD-induced mouse model of NAFLDReduced hepatic lipid accumulation and inflammation, decreased hepatic TC and TG and serum ALT and AST levels, and improved liver functionThe erythrocyte membrane conferred immune-evasive properties, whereas galactose modification promoted hepatocyte targeting; circRNA_0001805 sequestered miR-106a-5p and miR-320a and upregulated ABCA1 and CPT1, thereby promoting cholesterol efflux and fatty acid β-oxidation while suppressing NF-κB-mediated inflammatory signalingCell membrane-derived nanoparticles (CMNs).102Rosuvastatin (RS)In vitro MASLD/hepatocyte steatosis modelReduce hepatocellular lipid accumulation and alleviate MASLD-associated hepatocyte steatosisSelf-assembled biomimetic CMN membranes improve RS loading efficiency, cytocompatibility, and hepatocyte internalization, thereby enhancing the lipid-lowering activity of RSRed blood cell membrane-coated PLGA nanoparticles (RBC-PLGA NPs).103EzetimibeHFD-induced MAFLD rat modelEnhance liver-targeted delivery of ezetimibe, reduce dyslipidemia and hepatic lipid accumulation, and alleviate liver injury and inflammationRBC membrane coating prolongs circulation and increases hepatic deposition; ezetimibe modulates cholesterol absorption and hepatic metabolism/inflammation-related pathwaysDual-targeted nanoparticles hitchhiking on Lactobacillus rhamnosus bacterial ghosts (AXT@TWG@LBGs).104Astaxanthin (AXT)Choline-deficient HFD-induced NASH mouse modelAlleviate choline-deficient HFD-induced MASH and improve hepatic lipid accumulation, oxidative stress, inflammation, and insulin resistanceLBGs serve as oral delivery carriers to improve gastrointestinal stability, intestinal absorption, and hepatic accumulation of AXT@TWG; dual-targeted delivery enhances AXT bioavailability and reduces TG, FFA, MDA, and inflammatory cytokine levelsUDCA-modified liposome–ginger-derived exosome hybrid nanocarriers (GR-Exos@B).105BerberinePA-induced AML12 cell model and LPS-stimulated macrophage model; HFD-induced mouse model of NASHAttenuated steatosis, oxidative stress, and inflammation and improved insulin sensitivityUDCA-modified liposomes enhanced liver targeting, whereas ginger-derived exosomes facilitated macrophage targeting; the hybrid nanocarriers inhibited NLRP3 inflammasome activation and activated AMPK/AKT/IRS-1 signalingBlueberry-derived exosome-like nanoparticles (BELNs).106Blueberry-derived bioactive componentsRotenone-induced HepG2 model; HFD-induced MAFLD mouse modelReduce hepatic lipid deposition and improve insulin resistance and liver dysfunctionPromote Nrf2 nuclear translocation, enhance SOD/GSH antioxidant defenses, reduce ROS/MDA and apoptosis, and inhibit FAS/ACC1-mediated de novo lipogenesisPoria cocos-derived exosome-like nanovesicles (PCELNs).107Poria cocos-derived lipids, proteins, miRNAs, and other bioactive componentsFat emulsion-induced L02 cell steatosis model; HFD-induced MAFLD mouse modelImprove lipid accumulation, inflammation, and mitochondrial injuryActivate PINK1/Parkin-mediated mitophagy, reduce Ox-mtDNA leakage, and inhibit the NLRP3/caspase-1/IL-1β inflammasomeTangerine peel-derived exosome-like nanovesicles (TNVs).108Tangerine peel-derived bioactive components, including flavonoids, polyphenols, and lipidsdb/db mouse model of type 2 diabetes-associated hepatic steatosisReduce hepatic lipid deposition, improve insulin resistance, and regulate gut microbiota and bile acid metabolismPromote fatty acid β-oxidation, suppress lipogenesis, activate the FXR-SHP/FGF19 pathway, and increase SCFA production to modulate the gut-liver axisHoney vesicle-like nanoparticles (H-VLNs).109Honey-derived bioactive components, including miR5119, miR5108, and luteolinNaturally aged mouse model of spontaneous MASHAttenuate age-related MASH progression, suppress hepatic chronic inflammation, fibrosis, and nodule formation, and protect the aged liverAre taken up by hepatic Kupffer cells/macrophages and inhibit NLRP3 inflammasome, NF-κB, and C-JUN/JNK inflammatory signaling pathwaysTea-derived exosome-like nanoparticles (TELNs) from fermented tea.110Fermented tea-derived active metabolites, mainly including flavonoids, alkaloids, and lipidsHFD-induced MAFLD mouse modelAlleviate HFD-induced MAFLD and reduce blood lipids, hepatic lipid deposition, and inflammationAspergillus cristatus fermentation alters TELN particle size, yield, and metabolite composition, thereby enhancing lipid-lowering and anti-inflammatory effects; decreases TC, TG, LDL-C, ALT, AST, IL-6, and TNF-α levels and reduces hepatic lipid droplet accumulationPomegranate-derived exosome-like nanovesicles (PNVs).111Pomegranate-derived bioactive components enriched in ellagic acid (EA)WD-induced MASLD mouse modelAlleviate MASLD-associated leaky gut, hepatic steatosis, liver injury, and hepatic fibrosisPNVs accumulate in the intestine and liver, reduce serum endotoxin levels, restore barrier proteins including ZO-1, occludin, E-cadherin, and β-catenin, and modulate gut microbiota/oxidative stressBroccoli-derived exosome-like nanoparticles (BDENs).112Endogenous miRNAs and other bioactive componentsHFD-induced mouse model of MASLDAttenuated obesity, hepatic steatosis, and liver injury, improved intestinal barrier function, and suppressed hepatic inflammationUpregulated MUC2 and claudin-1 to restore the intestinal barrier, modulated the gut microbiota and bile acid metabolism, reduced LPS translocation to the liver, and decreased hepatic F4/80, IL-6, TNF-α, and IL-1β levelsTurmeric decoction-derived exosome-like nanoparticles (TELNs; extracted with 0%, 10%, or 20% ethanol).113Endogenous lipids and metabolites, primarily including sphingolipids, glycerolipids, and glycerophospholipidsHFD-induced mouse model of MASLDReduced hepatic lipid accumulation and improved dyslipidemia, liver injury, and systemic inflammation, with water-extracted TELNs exhibiting the greatest effectsDownregulated hepatic PLIN2, modulated lipid metabolism, and reduced serum and hepatic TG, TC, and LDL-C levels; these effects may be associated with bioactive lipid components such as sphingolipids in TELNs and reductions in IL-6 and TNF-α levelsExocarpium Citri Grandis-derived extracellular vesicle-like particles (ECG-EVLPs).114Natural plant-derived vesicular cargoHepG2 and AML12 cells; high-fat, high-fructose, and high-cholesterol diet-induced mouse model of MASLDAttenuated hepatic steatosis, inflammatory injury, and early-stage fibrosisDownregulated HOXC6-associated ERK1/2–SREBP1c signaling, thereby suppressing lipogenesis and inflammatory responsesSargassum fusiforme-derived nanovesicles (SF-NVs; HFMC as the oral formulation).115Endogenous bioactive components, primarily including elemolLPS-induced inflammatory models in RAW264.7 and Kupffer cells; HFD-induced mouse model of MASHAttenuated hepatic steatosis, inflammation, and liver injury and improved glucose and lipid metabolism and intestinal barrier functionActivated Nrf2/HO-1 signaling and inhibited the MyD88/IKK/IκB/NF-κB pathway; it also suppressed FASN, promoted PGC-1α/CPT1-mediated fatty acid oxidation and MTTP-mediated lipid export, and restored intestinal barrier homeostasisNotes: Some nanosystems may be relevant to more than one pathological process, hepatic cell type, or nanoplatform category. They are listed according to their dominant platform type or primary therapeutic function, while additional mechanisms and target-cell interactions are discussed in the corresponding text sections. Nanoparticle-Based Therapeutic Strategies for MASLD and Their Potential Mechanisms Notes: Some nanosystems may be relevant to more than one pathological process, hepatic cell type, or nanoplatform category. They are listed according to their dominant platform type or primary therapeutic function, while additional mechanisms and target-cell interactions are discussed in the corresponding text sections. PubMed and Web of Science were searched from database inception to July 2026 using combinations of the terms “metabolic dysfunction-associated steatotic liver disease,” “MASLD,” “nonalcoholic fatty liver disease,” “NAFLD,” “metabolic dysfunction-associated steatohepatitis,” “MASH,” “nonalcoholic steatohepatitis,” “NASH,” “nanoparticle,” “nanomedicine,” and “nanocarrier.” Additional relevant studies were identified by screening the reference lists of key reviews and eligible original articles. Based on the literature identified through the above search, this review evaluates nanodelivery systems for MASLD from the perspectives of therapeutic mechanisms, platform design, functional advantages, and translational limitations. In contrast to previous reviews that mainly summarize MASLD-related nanotherapies by nanomaterial type or individual therapeutic application, this review starts from the therapeutic needs of MASLD and further discusses how different nanodelivery platforms may contribute to the modulation of key pathological processes, targeted delivery to major hepatic cell populations, and the management of clinical translation barriers, thereby providing theoretical support for the development of precise, effective, and clinically translatable nanotherapeutic strategies for MASLD. Targeted Nanodelivery Strategies for Key Pathological Processes in MASLD Dysregulated Lipid Metabolism Dysregulated lipid metabolism is one of the central events in the development of MASLD and is primarily characterized by abnormal lipid accumulation in hepatocytes.116,117 Studies have shown that hepatic de novo lipogenesis (DNL) is markedly enhanced in MASLD, accompanied by the upregulation of key lipogenic enzymes, including sterol regulatory element-binding protein 1c (SREBP-1c), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FASN), thereby promoting the synthesis of fatty acids and triglycerides.118 Meanwhile, fatty acid β-oxidation is impaired, particularly through suppression of the peroxisome proliferator-activated receptor α (PPARα)-regulated fatty acid oxidation pathway, which further exacerbates lipid accumulation in hepatocytes.119 In addition, abnormalities in the synthesis and secretion of very-low-density lipoprotein (VLDL) can limit hepatic lipid export and thereby aggravate lipid deposition.120 Excessive lipid accumulation in hepatocytes can induce lipotoxicity, further leading to cellular injury and inflammatory responses.121,122 Currently, various nanotechnology-based drug delivery systems, such as solid lipid nanoparticles, self-nanoemulsifying systems, and liposomes, have been shown to enhance the in vivo absorption and therapeutic efficacy of lipid-lowering agents. These effects are reflected by reductions in serum total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels, together with increased high-density lipoprotein cholesterol (HDL-C) levels.123–125 In addition to improving systemic lipid profiles, some therapeutic nanoformulations can directly regulate multiple key processes involved in maintaining hepatic lipid homeostasis. For example, cationic nanoparticles efficiently loaded with naringenin (NP-NAR) reduced hepatic expression of CD36, ACC, and FASN, thereby limiting fatty acid uptake and de novo lipogenesis, while promoting fatty acid oxidation through activation of PPAR-related signaling pathways.50 In addition, delivery of MST1 using a redox-responsive polymeric nanocarrier modulated the AMPK/SREBP-1c signaling axis and its downstream lipid metabolic regulators, thereby improving insulin resistance and reducing hepatic lipid accumulation.61 Bilirubin nanoparticles reduced hepatic ceramide production and remodeled the hepatic lipid profile in obese mice, whereas CRISPR–Cas9 lipid nanoparticles targeting Rubicon attenuated hepatic lipid deposition by restoring autophagic function and regulating CD36 expression and glycerophospholipid metabolism.81,126 Some nanoformulations may also indirectly facilitate the restoration of hepatic lipid metabolism by improving insulin sensitivity, modulating the gut microbiota, and restoring gut–liver axis homeostasis.50,108 With continuing advances in nanodelivery technologies, increasing attention has been directed toward the use of lipid- or polymer-based nanocarriers to deliver nucleic acid therapeutics, including siRNAs, gene-expression plasmids, and CRISPR–Cas9 systems, for the modulation of MST1, Rubicon, HIF-1α, and other molecular targets implicated in MASLD progression.61,81,108 Oxidative Stress and Mitochondrial Dysfunction Oxidative stress and mitochondrial dysfunction are considered major driving factors in the onset and progression of MASLD.127,128 When intracellular lipid burden increases, mitochondrial β-oxidation activity is correspondingly enhanced, leading to elevated electron transport chain flux and an increased risk of electron leakage. During this process, dysfunction of the electron transport chain occurs, particularly due to the reduced efficiency of oxygen reduction mediated by cytochrome c oxidase (complex IV), resulting in the ineffective transfer of electrons to the terminal acceptor. Consequently, proton transport across the inner mitochondrial membrane is impaired, leading to a reduction in mitochondrial membrane potential (ΔΨm), suppression of ATP synthase activity, and ultimately impaired energy production.129 Meanwhile, incompletely transferred electrons can directly react with molecular oxygen to generate excessive ROS.130,131 In addition, mitochondrial CYP2E1 is also an important source of ROS.130 Excessive ROS further aggravates mitochondrial dysfunction through mechanisms associated with mitochondrial DNA damage and the accumulation of lipid peroxidation products, such as MDA and 4-HNE, which promote electron leakage within the electron transport chain and thereby form a vicious cycle.132 In recent years, several functional nanoplatforms have demonstrated multifaceted regulatory effects in alleviating oxidative stress and mitochondrial dysfunction. For example, some nanomaterials can attenuate oxidative stress by reducing MDA levels and enhancing the activities of antioxidant enzymes such as SOD and GPx-1, while also achieving subcellular targeted delivery to the endoplasmic reticulum and mitochondria.123,133 In addition, cerium oxide nanoparticles, owing to their reversible Ce3⁺/Ce4⁺ redox cycling capability, are regarded as important ROS scavengers. Experimental studies have demonstrated that they can eliminate excessive ROS, alleviate lipid peroxidation, and maintain mitochondrial functional stability, thereby mitigating oxidative stress-related liver injury.134 Meanwhile, other functional nanosystems have shown similar regulatory effects. Li et al,135 reported that Mino@ZIF-8 nanoparticles could restore cellular energy metabolism by reconstructing the metabolic balance between glycolysis and OXPHOS, while alleviating oxidative damage, repairing damaged mitochondria, and suppressing inflammatory responses through regulation of the AKT/GSK3β/NRF2 signaling pathway. Zhang et al,136 found that T-A-Ls, a newly developed TPP-modified nanoliposome incorporating natural ATS compounds, exhibited potent antioxidant activity and mitochondrial-targeting properties. These nanoliposomes significantly reduced ROS levels, restored mitochondrial membrane potential, and improved respiratory function, while simultaneously downregulating RAGE and iNOS expression and upregulating Nrf2 and HO-1 expression, thereby suppressing inflammatory responses and alleviating oxidative stress. Inflammatory Responses and Innate Immune Activation During the progression of MASLD, sustained activation of hepatic inflammation is a key driver of disease transition from simple steatosis to more advanced stages.137 Excessive lipid accumulation and the resulting lipotoxicity can stimulate the hepatic innate immune system, promoting the polarization of Kupffer cells toward a pro-inflammatory M1 phenotype and facilitating the recruitment and infiltration of peripheral monocytes, thereby amplifying the local inflammatory microenvironment.138 Meanwhile, activation of the NLRP3 inflammasome further promotes the release of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β).139 These inflammatory mediators not only directly contribute to hepatocyte injury and cell death but also accelerate liver fibrosis by activating HSCs and promoting extracellular matrix deposition.22 In addition, oxidative stress and mitochondrial dysfunction can act as upstream signals that further amplify inflammatory responses, forming a positive feedback loop of “metabolic dysfunction–oxidative stress–inflammation” and driving the continuous progression of MASLD.127 Studies have shown that NPs can function not only as adjuvants that nonspecifically enhance immune responses but also as important tools for inducing or modulating innate immune memory.140 Current research on the interactions between NPs and the immune system has mainly focused on circulating monocytes and tissue-resident macrophages,141 the latter of which are key effector cells in hepatic inflammation.142 Lin et al,143 reported that nanocarriers can regulate macrophage behavior through their physicochemical properties, enabling targeted delivery to immune cells and further influencing macrophage polarization, for example, by inhibiting M1 polarization or promoting M2 transition, thereby improving the inflammatory microenvironment. Su et al,144 demonstrated that NPs can rapidly alleviate oxidative stress, inhibit M1 macrophage polarization, reduce inflammatory levels, improve the pro-inflammatory hepatic microenvironment in ob/ob mice, and attenuate hepatic steatosis. In addition, redox-active nanomaterials can further suppress inflammatory responses by scavenging excessive ROS and alleviating oxidative stress.145 Insulin Resistance Insulin resistance (IR) is an important metabolic basis underlying the onset and progression of MASLD and serves as a critical link connecting obesity, type 2 diabetes, lipid deposition, inflammatory responses, and liver fibrosis.146 Under physiological conditions, insulin promotes glycogen synthesis, suppresses gluconeogenesis, and maintains lipid metabolic homeostasis through the IRS/PI3K/AKT signaling pathway.147 However, under conditions of obesity, lipotoxicity, and chronic low-grade inflammation, free fatty acids, ceramides, diacylglycerols, and inflammatory cytokines interfere with insulin signaling transduction pathways such as IRS-1/AKT, resulting in reduced hepatocellular responsiveness to insulin.148 On the one hand, IR weakens the inhibitory effect of insulin on hepatic gluconeogenesis, thereby promoting hyperglycemia and hyperinsulinemia; on the other hand, it fails to effectively suppress hepatic DNL, which further aggravates hepatocellular lipid accumulation and lipotoxic injury.149 This phenomenon of “selective insulin resistance” further amplifies oxidative stress, inflammatory responses, and cellular injury, thereby driving the progression of MASLD from simple steatosis to MASH, fibrosis, and even cirrhosis.150 Targeted nano-delivery strategies aimed at this key pathological process primarily exert therapeutic effects by improving hepatic insulin signaling, regulating lipid metabolism, and alleviating inflammation and oxidative stress.151,152 For example, Li et al,153 reported that fucoxanthin-loaded oxidized milrinone self-assembled nanoparticles (Fx-OEP) could reduce ROS accumulation through activation of the Nrf2/HO-1 pathway, restore IRS1/GLUT4 signaling, and promote glucose uptake, thereby alleviating IR in HepG2 cells. Zai et al,65 developed a liver-targeted hybrid nanoparticle self-assembled from polymetformin, penetratin, and DSPE-PEG2000 for the delivery of the IL-22 gene, while simultaneously exhibiting metformin-like metabolic regulatory effects. This system promoted targeted and sustained hepatic expression of IL-22 and significantly alleviated hepatic steatosis, restored insulin sensitivity, and improved metabolic syndrome in HFD-fed mice. These effects may be associated with activation of the STAT3/Erk1/2 and Nrf2/SOD1 signaling pathways, as well as regulation of lipid metabolism-related gene expression. Gut–Liver Axis The gut–liver axis is an important regulatory network involved in the development and progression of MASLD. It mainly encompasses interactions among the gut microbiota, intestinal mucosal barrier, portal circulation, bile acid metabolism, and hepatic immune-inflammatory responses.154 Under physiological conditions, an intact intestinal mucosal barrier restricts the excessive translocation of gut-derived endotoxins and microbial metabolites into the portal venous system, thereby maintaining hepatic immune homeostasis.155 However, during MASLD progression, gut dysbiosis is often accompanied by reduced expression of tight junction proteins and impairment of the mucosal mechanical barrier, leading to increased intestinal permeability.156,157 Once barrier function is compromised, gut-derived stimuli, including lipopolysaccharide (LPS), bacteria, and their metabolites, can more readily enter the liver through the portal vein, activate Kupffer cells (KCs) and related inflammatory pathways, and induce the release of inflammatory cytokines, thereby further aggravating hepatocyte injury, dysregulated lipid metabolism, and MASLD progression.157 Studies have shown that orally administered NPs can interact with intestinal pH, the mucus layer, epithelial absorption systems, the food matrix, and the gut microbiota. Through designs such as surface functionalization, pH responsiveness, or mucoadhesion, nanocarriers can improve the gastrointestinal stability of bioactive compounds and enable intestinal site-specific release or systemic delivery, thereby providing a delivery platform for modulating the gut microbiota, repairing the intestinal barrier, and improving MASLD-associated gut–liver axis dysregulation.158 Zhu et al,159 found that folate-modified TPGS nanoparticles delivering XBP1s siRNA (FT@XBP1) alleviated NASH by improving gut dysbiosis and intestinal mucosal barrier injury. In FFC diet-induced NASH mice, this system reduced hepatic steatosis, inflammation, endoplasmic reticulum stress, and fibrosis. It also maintained intestinal barrier integrity by upregulating ZO-1 expression and reducing gut-derived endotoxemia and inflammatory signaling activation, thereby delaying NASH progression. Liver Fibrosis Liver fibrosis is a key determinant affecting the long-term prognosis of patients with MASLD,160 and increasing fibrosis severity is generally associated with reduced survival rates and a higher risk of adverse clinical outcomes.161 Pathologically, liver fibrosis represents the consequence of an aberrant wound-healing response following chronic liver injury and is primarily characterized by excessive deposition of ECM and tissue structural remodeling.162 During MASLD progression, multiple stimuli, including hepatocellular lipotoxic injury, release of inflammatory cytokines, DAMPs, and PAMPs, collectively contribute to the activation of HSCs located in the space of Disse.152 Upon activation, HSCs progressively lose intracellular lipid droplets and transdifferentiate into myofibroblast-like cells with proliferative, migratory, contractile, and ECM-secreting capacities, thereby becoming the major effector cells responsible for collagen deposition and fibrosis progression.163 Meanwhile, an imbalance between MMPs and TIMPs restricts ECM degradation, resulting in persistent matrix accumulation and further promoting the progression of liver fibrosis.164 Studies have demonstrated that nanosystems can partially overcome in vivo delivery barriers, including clearance by the mononuclear phagocyte system, reduced fenestration caused by hepatic sinusoidal capillarization, and obstruction by dense ECM, thereby enhancing the accumulation of antifibrotic agents and nucleic acid therapeutics in activated HSCs. The delivered cargos include small-molecule drugs, siRNA, shRNA, miRNA, and CRISPR-Cas9 gene-editing tools, which exert antifibrotic effects by inhibiting HSC activation, inducing HSC apoptosis or senescence, and regulating metabolic and inflammatory signaling pathways.165 Li et al,166 reported that pPB-SSL-IFN-γ could selectively target activated HSCs (aHSCs) and effectively inhibit HSC proliferation in vitro. In a thioacetamide-induced mouse liver fibrosis model, this system significantly alleviated fibrosis severity. Moreover, liposomal delivery prolonged the in vivo circulation half-life of IFN-γ and reduced potential adverse effects caused by non-target distribution. Ribera et al,167 developed gold nanorods surface-modified with anti-PDGFRβ antibodies for the specific targeting of activated HSCs. In a CCl4-induced mouse liver fibrosis model, these nanorods achieved targeted accumulation in aHSCs, reduced hepatic inflammation, and attenuated fibrosis. In addition, inorganic nanomaterials such as titanium dioxide (TiO2) nanoparticles and silicon dioxide (SiO2) nanoparticles have also been reported to exhibit certain antifibrotic potential in vitro through their effects on HSCs.168 Collectively, these pathological processes are highly interconnected and jointly drive the initiation and progression of MASLD. As summarized in Figure 2, targeted nanodelivery systems can intervene at multiple pathological nodes by regulating lipid metabolism, alleviating oxidative stress and mitochondrial dysfunction, suppressing inflammation and innate immune activation, improving insulin resistance, restoring homeostasis of the gut–liver axis, and inhibiting liver fibrosis. Key pathological processes in MASLD and corresponding targeted nanodelivery strategies. The development and progression of MASLD involve multiple interconnected pathological processes, including dysregulated lipid metabolism, oxidative stress and mitochondrial dysfunction, inflammation and innate immune activation, insulin resistance, gut–liver axis dysregulation, and liver fibrosis. For dysregulated lipid metabolism, nanodelivery systems can deliver lipid-lowering agents and target lipogenic pathways such as SREBP-1c/ACC/FASN, thereby reducing hepatocellular lipid uptake, abnormal fatty acid β-oxidation, lipotoxic injury, and hepatic lipid accumulation. For oxidative stress and mitochondrial dysfunction, antioxidant nanosystems can scavenge excessive ROS, reduce oxidative damage products such as MDA and 4-HNE, and restore mitochondrial function and ATP production. For inflammation and innate immune activation, nanocarriers can regulate Kupffer cell/macrophage activation, inhibit NLRP3 inflammasome activation and the release of pro-inflammatory cytokines such as TNF-α and IL-1β, thereby alleviating hepatic inflammation. For insulin resistance, functional nanoparticles can improve impaired IRS/PI3K/AKT insulin signaling, promote glucose uptake and metabolism, and modulate related signaling pathways such as Nrf2/HO-1 and STAT3. For gut–liver axis dysregulation, oral or intestinal-targeted nanodelivery systems can enhance intestinal targeting, repair the intestinal barrier, modulate gut dysbiosis, and reduce liver inflammation induced by the translocation of LPS, bacteria, and their metabolites into the liver via the portal vein. For liver fibrosis, nanocarriers can target activated hepatic stellate cells, deliver anti-fibrotic drugs or nucleic acid therapeutics, inhibit HSC activation, regulate MMP/TIMP imbalance, and promote extracellular matrix remodeling. Overall, targeted nanodelivery strategies can intervene in the core pathological processes of MASLD through multiple mechanisms, thereby reducing steatosis, alleviating oxidative stress, suppressing inflammation, improving insulin resistance, restoring gut–liver axis homeostasis, and delaying the progression of liver fibrosis. In the figure, ↑ indicates an increase or upregulation, whereas ↓ indicates a decrease, impairment, or downregulation. Red crosses (×) indicate impaired or interrupted signaling steps in the IRS/PI3K/AKT pathway. Black arrows pointing toward the central liver indicate the contribution of each pathological process to MASLD development and progression, whereas arrows within the individual schematics indicate the direction of signaling, transport, cellular transition, or pathological progression. Targeted Nanodelivery Strategies for Key Hepatic Cell Types in MASLD Hepatocyte-Targeted Nanodelivery Strategies Hepatocytes are the major parenchymal cells responsible for maintaining hepatic lipid, glucose, and protein metabolism, as well as detoxification functions.169 They are also the principal effector cells involved in dysregulated lipid metabolism, lipotoxic injury, and parenchymal damage in MASLD.170 Persistent lipid overload, oxidative stress, and inflammatory stimulation can lead to hepatocyte dysfunction, further aggravating disruption of hepatic metabolic homeostasis and disease progression.171 Given the central role of hepatocytes in the development and progression of MASLD, enhancing the selective accumulation and intracellular delivery efficiency of therapeutic agents in hepatocytes has become an important direction for optimizing nanotherapeutic strategies for MASLD. Studies have shown that nanodelivery systems can selectively deliver hepatoprotective bioactive agents to hepatocytes, thereby attenuating hepatocellular injury and helping to maintain hepatic functional stability.172,173 Currently, hepatocyte-targeted delivery strategies mainly focus on the asialoglycoprotein receptor (ASGPR). ASGPR is predominantly expressed on the surface of hepatocytes, with minimal expression in extrahepatic cells, and is characterized by high receptor density and continuous recycling-mediated endocytosis. These properties make ASGPR an ideal molecular target for receptor-mediated hepatocyte-specific drug delivery.174,175 Based on its specific recognition of terminal galactose (Gal) and N-acetylgalactosamine (GalNAc) ligands, various ASGPR-mediated delivery strategies have been developed, including GalNAc-conjugated siRNAs or antisense oligonucleotides, as well as hepatocyte-targeted systems based on NPs or polymeric carriers.176,177 Among these, GalNAc-conjugated nucleic acid therapeutics represent the most mature approach, with several agents already applied in diseases such as hypercholesterolemia, transthyretin amyloidosis, and primary hyperoxaluria.175 In addition to ligand-conjugation strategies, lipid nanoparticles (LNPs) are among the most mature and widely used platforms for hepatic nucleic acid delivery. As a delivery system with a high degree of clinical translatability, LNPs not only improve the stability and bioavailability of nucleic acid therapeutics but also possess an inherent advantage for hepatic accumulation.178,179 Furthermore, emerging nanocarriers, such as lipopeptide nanoparticles (LPNPs), have also shown promising application potential. These systems can achieve efficient and relatively specific siRNA delivery to hepatocytes through dynamin-dependent macropinocytosis.180 Overall, the integration of ligand-modification strategies with nanodelivery platforms provides important technical support for the precise intervention of MASLD-associated dysregulated lipid metabolism and hepatocellular injury. Hepatic Stellate Cell-Targeted Nano-Delivery Strategies Under physiological conditions, HSCs remain in a quiescent state and are primarily responsible for vitamin A storage and maintenance of hepatic sinusoidal microenvironmental homeostasis.181 However, under persistent stimulation induced by chronic metabolic injury, lipotoxicity, oxidative stress, and inflammation, quiescent HSCs can be activated and transdifferentiate into myofibroblast-like cells. Activated HSCs exhibit enhanced proliferative, migratory, and contractile capacities, accompanied by upregulation of activation markers such as α-SMA, as well as excessive synthesis and secretion of ECM components, including type I and type III collagen, ultimately resulting in abnormal ECM deposition and intrahepatic fibrotic scar formation.182 This process is further regulated by the hepatic immune microenvironment, particularly through Kupffer cells and recruited monocytes/macrophages, which secrete profibrotic mediators such as TGF-β and PDGF, thereby further promoting HSC activation, proliferation, and ECM production.183,184 Compared with conventional drug administration, nano-delivery systems can improve the local accumulation efficiency of therapeutic agents in the liver, particularly within activated HSCs, while also helping to reduce systemic adverse effects.185 Currently, HSC-targeted nanotherapeutic strategies mainly involve drug or gene delivery systems based on various nanomaterials, including lipid nanoparticles, polymeric nanoparticles, inorganic nanoparticles, and extracellular vesicles. These systems achieve active targeting of activated HSCs through surface modification with specific targeting ligands, such as vitamin A, retinoic acid, PDGFR-β-targeting pPB peptide, CD44-targeting hyaluronic acid, type VI collagen receptor-targeting RGD peptide, fibronectin-targeting CREKA peptide, and Sig-1R-targeting AEA.165 For example, Wang et al186 developed hyaluronic acid-modified liposomes co-delivering all-trans retinoic acid and L-arginine. This system utilized NO-mediated pathological barrier remodeling to enhance nanoparticle accumulation in activated HSCs, while retinoic acid release induced HSC deactivation and reduced collagen deposition. Lai et al,187 further demonstrated that vitamin A-functionalized fluorinated peptide/lipid hybrid nanoparticles could co-deliver sorafenib and siHSP47. By enhancing targeting specificity toward activated HSCs and synergistically inhibiting collagen production while promoting collagen degradation, these nanoparticles ultimately alleviated collagen deposition and liver fibrosis. Liver Macrophage-Targeted Nano-Delivery Strategies Liver macrophages mainly consist of liver-resident Kupffer cells (KCs) and monocyte-derived macrophages and represent important cellular populations involved in hepatic innate immune defense and inflammatory regulation.138 Under physiological conditions, KCs possess strong phagocytic and clearance capabilities, enabling them to recognize and eliminate blood-borne foreign substances, pathogens, and cellular debris. This characteristic also provides a biological basis for macrophage uptake-mediated liver-targeted delivery. However, under persistent stimulation induced by lipid overload, oxidative stress, and gut-derived endotoxins, KCs become aberrantly activated and contribute to inflammatory amplification, HSC activation, and MASLD progression through the release of inflammatory cytokines, chemokines, and profibrotic mediators.188 Therefore, targeted regulation of liver macrophage phenotype and function has emerged as a potential therapeutic strategy for MASLD, and nanoparticles have demonstrated unique application value in this field.189,190 The particle size, morphology, and surface charge of nanoparticles themselves can also influence hepatic uptake and cellular distribution. Studies have shown that spherical, positively charged nanoparticles with diameters greater than 200 nm are more readily internalized by Kupffer cells.152 Based on these properties, various nano-delivery systems, including solid lipid nanoparticles, liposomes, and polymeric nanoparticles, have been employed for liver macrophage-targeted delivery.191 These nanocarriers can deliver therapeutic agents into macrophages through passive uptake, physicochemical property modulation, or ligand-mediated active targeting, thereby improving local immunomodulatory efficiency. Previous studies have utilized liposomal transfection strategies to deliver dextran encapsulating sphingosine-1-phosphate receptor 2 (S1PR2) siRNA into macrophages, thereby suppressing NLRP3 inflammasome activation, alleviating hepatic inflammation, and delaying fibrosis progression.192 Zhu et al,193 further developed the FT@XBP1 nanosystem for the specific delivery of Xbp1 siRNA to liver macrophages. This system inhibited spliced XBP1 expression, promoted repolarization of M1 macrophages toward the M2 phenotype, reduced the release of proinflammatory cytokines, and alleviated MASH-related liver injury and fibrosis through suppression of HSC activation. Melgar et al194 constructed a positively charged graphene nanostar/PAMAM-G5 delivery system capable of delivering MMP-9 plasmids to inflammatory macrophages in fibrotic livers. By upregulating MMP-9 expression, this system promoted collagen degradation and reduced collagen deposition, while MMP-9 overexpression further facilitated macrophage polarization toward the reparative M2 phenotype. Similarly, Wang et al,195 reported that TSG-6@CaP@BSA nanoparticles (CaP, calcium phosphate) promoted macrophage polarization toward the M2 phenotype and upregulated the expression of matrix metalloproteinase 12 (MMP12). MMP12 subsequently inhibited HSC activation and reduced the release of proinflammatory cytokines, thereby exerting antifibrotic and anti-inflammatory effects. Kurniawan et al,52 developed PLGA nanoparticles encapsulating the SYK inhibitor R406, which alleviated inflammation, steatosis, and fibrosis in a NASH mouse model by suppressing the proinflammatory macrophage phenotype and reducing NO release and related marker expression in M1 macrophages. In addition, Maeda et al,196 designed mannose-modified human serum albumin nano-antioxidants that utilized mannose-mediated KC uptake and the ROS-scavenging ability of polythiol groups to alleviate oxidative stress and suppress inflammatory responses. Furthermore, this group developed the SNO-Man-HSA nanosystem through S-nitrosylation, enabling the co-delivery of NO donors and thiol groups to the liver. This system demonstrated protective effects in improving intrahepatic blood flow, enhancing antioxidant activity, and alleviating NASH-related liver injury.197 Liver Sinusoidal Endothelial Cell-Targeted Nano-Delivery Strategies LSECs are important non-parenchymal cells constituting the hepatic sinusoidal microenvironment. Located between the bloodstream and hepatocytes, they possess abundant fenestrated structures as well as strong endocytic, clearance, and immunoregulatory capacities.198 Under physiological conditions, LSECs play protective roles in hepatic metabolic homeostasis and antifibrotic processes by maintaining sinusoidal permeability, regulating substance exchange, secreting NO, and preserving HSC quiescence.199 However, during MASLD progression, lipotoxicity, oxidative stress, inflammatory cytokines, and endotoxin stimulation induce LSEC dysfunction, leading to progressive defenestration and capillarization, accompanied by basement membrane formation, increased adhesion molecule expression, and reduced NO production. These alterations not only impair hepatic sinusoidal material exchange but also promote inflammatory cell adhesion and infiltration, while facilitating HSC activation and ECM deposition through paracrine signaling, thereby driving the progression of steatohepatitis and fibrosis.198,200 Current LSEC-targeted delivery strategies mainly aim to regulate sinusoidal endothelial function, improve hepatic sinusoidal microcirculation, restore endothelial fenestration, suppress endothelial inflammatory activation, and block profibrotic signaling from LSECs to HSCs.201 In the design of delivery systems, the physicochemical characteristics of nanocarriers, including particle size, surface charge, and ligand modification, can influence their distribution behavior within hepatic sinusoids, endothelial penetration capacity, and cellular uptake efficiency, thereby serving as critical determinants for precise LSEC-targeted delivery.202 Hide et al,203 developed simvastatin-loaded Pluronic polymeric micelles that preferentially accumulated in the liver and were efficiently internalized by LSECs. By improving the LSEC phenotype, enhancing NO bioavailability, and reducing intrahepatic vascular resistance, these micelles more effectively alleviated portal hypertension than free simvastatin in chronic liver disease models, while also exhibiting lower toxicity. Chen et al,204 further suggested that improving LSEC capillarization and restoring the hepatic sinusoidal endothelial barrier and vascular homeostasis could facilitate normalization of the abnormal sinusoidal microenvironment, thereby enhancing drug delivery efficiency in hepatic lesions and synergistically regulating vascular abnormalities and the immunosuppressive microenvironment. In addition, Wang et al,205 developed Topas Particle Conjugates (TPCs), which preferentially targeted LSECs and delivered disease-associated antigenic peptides. By utilizing the tolerogenic antigen-presenting function of LSECs, TPCs induced antigen-specific Treg generation and T-cell anergy, thereby alleviating immune injury in multiple CD4⁺ T cell-mediated inflammatory and autoimmune disease models. Multicellular Co-Delivery Strategies MASLD is not driven by abnormalities in a single cell type but rather results from multicellular interactions among hepatocytes, Kupffer cells/monocyte-derived macrophages, HSCs, LSECs, and gut-associated immune cells.206 Therefore, compared with single-cell-targeted delivery, multicellular co-delivery strategies place greater emphasis on simultaneously intervening in multiple key cellular nodes within the same pathological network, thereby achieving integrated regulation of lipid deposition, inflammatory amplification, vascular barrier remodeling, and fibrotic progression. At present, various cell-targeting strategies have been applied in targeted delivery systems for liver diseases. For example, Lin et al,207 developed a ROS- and pH-dual-responsive polymeric micelle loaded with polydatin (PD-MC). This nanomedicine exploits the high ROS microenvironment in fibrotic liver tissue and the acidic lysosomal pH to achieve site-specific drug release at pathological lesions. Studies have shown that PD-MC not only alleviates macrophage-mediated inflammatory responses by scavenging ROS and inhibiting the TLR4/NF-κB p65 signaling pathway, but also significantly reduces NOX4 expression and ROS levels in HSCs, thereby suppressing HSC activation and collagen synthesis. Meanwhile, PD-MC effectively protects hepatocytes from apoptosis. More importantly, by simultaneously targeting multiple cellular nodes, including hepatocytes, macrophages, and HSCs, and blocking paracrine crosstalk between macrophages and HSCs, this strategy synergistically improves liver fibrosis at the multicellular level. Sun et al,208 constructed a neutrophil membrane-biomimetic sequential nanodelivery system. In this system, NCM@AtAm first targets inflammatory regions in the fibrotic liver, where atorvastatin and ambrisentan act synergistically to promote LSEC functional normalization, restore liver sinusoidal fenestrations, and overcome the capillarized vascular barrier. Subsequently, vitamin A-modified VNCM@Bai further penetrates into the space of Disse and targets activated HSCs to deliver the antifibrotic component Bai. Ultimately, this sequential strategy inhibits HSC activation by regulating the PPARγ/TGF-β1 and STAT1/Smad7 signaling pathways, thereby achieving effective intervention against liver fibrosis. These examples further highlight that some multifunctional nanosystems are difficult to assign exclusively to a single pathological process or cellular category, because their therapeutic effects often depend on coordinated regulation of multiple hepatic cell populations and disease processes. Overall, MASLD progression is driven by complex crosstalk among hepatocytes, liver macrophages, HSCs, LSECs, and gut-derived signals. As illustrated in Figure 3, nanoparticle-based delivery systems can target these interconnected cellular and pathological nodes to reduce hepatocellular lipotoxicity, regulate macrophage-mediated inflammation, restore LSEC function, suppress HSC activation and extracellular matrix deposition, and improve gut–liver axis dysregulation. Pathogenic network of MASLD and major intervention nodes of nanoparticle-based delivery systems. MASLD progression involves a complex multicellular network comprising hepatocellular lipid accumulation and lipotoxicity, damage- and inflammation-related signaling, Kupffer cell/monocyte-derived macrophage activation, liver sinusoidal endothelial cell dysfunction, hepatic stellate cell activation, extracellular matrix deposition, and gut–liver axis dysregulation. Nanoparticle-based delivery systems may intervene at multiple pathological nodes by targeting hepatocytes, macrophages, hepatic stellate cells, liver sinusoidal endothelial cells, and the gut–liver axis. Representative strategies include lipid-lowering and antioxidant delivery to hepatocytes, macrophage-targeted anti-inflammatory or polarization-modulating approaches, anti-fibrotic delivery to hepatic stellate cells, endothelial-protective strategies for liver sinusoidal endothelial cells, and microbiota- or barrier-directed interventions along the gut–liver axis. These approaches may reduce lipid accumulation and oxidative injury, suppress inflammatory amplification, improve endothelial dysfunction, inhibit hepatic stellate cell activation, and limit fibrogenesis. In the figure, ↑ indicates increased expression, accumulation, or activity. Solid arrows indicate direct pathological signaling, stimulation, activation, or cellular transition, whereas dashed arrows indicate indirect regulatory effects. NP Systems in MASLD The therapeutic performance of nanodelivery systems in MASLD depends not only on the pathological process being targeted and the intended hepatic cell population, but also on the physicochemical and structural properties of the carrier. Conventional free drugs are often limited by poor aqueous solubility, insufficient in vivo stability, limited effective intrahepatic exposure, and weak target-cell selectivity. NP delivery systems can improve drug stability, bioavailability, and hepatic accumulation by modulating particle size, surface charge, hydrophilicity/hydrophobicity, drug release behavior, and targeting ligand modification. They can also facilitate drug delivery to key hepatic cell types, including hepatocytes, Kupffer cells, HSCs, and LSECs. Based on material composition and structural characteristics, MASLD-related nanodelivery systems can be broadly classified into inorganic nanoparticles, polymeric nanoparticles, liposomes, and lipid-based nanosystems, and bio-derived and biomimetic nanosystems (Figure 4). Through different functional payloads, these systems can intervene in key pathological processes, including lipid deposition, oxidative stress, inflammation, fibrosis, and gut–liver axis dysregulation (Table 1). This classification is intended to facilitate comparison rather than to define mutually exclusive categories, as some nanosystems combine multiple material components, targeting ligands, stimuli-responsive properties, or biological functions. Major nanoparticle platforms for MASLD therapy: functional features and translational limitations. Nanoparticle-based delivery systems for MASLD therapy can be broadly classified into five major categories: inorganic nanoparticles, polymeric nanoparticles, liposomes, bio-derived systems, and virus-like particles (VLPs). Inorganic nanoparticles, represented here by cerium oxide (CeO2), iron oxide (Fe3O4), and gold (Au) nanoparticles, are characterized by high stability, antioxidant activity, imaging potential, and ease of surface modification, but their long-term accumulation, potential chronic toxicity, clearance, and biodegradability remain important concerns. Polymeric nanoparticles, including systems based on PLGA, PCL, chitosan, and PEG–PLGA, offer tunable structures, controlled release, good drug-loading capacity, and flexible ligand modification, although limited penetration into fibrotic extracellular matrix, degradation variability, and challenges in scale-up and reproducibility remain to be addressed. Liposomes, including conventional liposomes and PEGylated liposomes, exhibit good biocompatibility, broad applicability for drug encapsulation, and relatively mature clinical translation experience, but are still limited by mononuclear phagocyte system (MPS) clearance, nonspecific accumulation, and batch-to-batch variability. Bio-derived systems, such as extracellular vesicles (EVs), mesenchymal stem cell-derived extracellular vesicles (MSC-EVs), and food-derived exosome-like nanoparticles, possess natural biocompatibility, intrinsic targeting ability, low immunogenicity, and intercellular communication capability; however, source heterogeneity, difficulties in large-scale production, cargo-loading efficiency, and quality control remain major translational barriers. VLP-based systems, including HBV-derived VLPs, HEV-derived VLPs, and engineered VLPs, offer hepatocyte-targeting potential, multivalent ligand display, protein/nucleic acid delivery capability, and transient gene editing potential, but face limitations related to capsid immunogenicity, pre-existing immunity, repeated-dose administration, and limited MASLD-specific evidence. In the figure, green check-mark icons indicate the major advantages of each platform, whereas red warning-triangle icons indicate their principal limitations and translational challenges. Inorganic Nanoparticles Inorganic NPs mainly include metal and metal oxide nanoparticles, silica nanoparticles, carbon-based nanomaterials, and magnetic iron oxide nanoparticles. These NPs generally exhibit high structural stability, ease of surface modification, and strong drug-loading capacity, and have therefore attracted increasing attention for the intervention of hepatic inflammation, oxidative stress, and fibrosis.28 Cerium oxide nanoparticles (CeO2 NPs) exhibit multienzyme-mimetic antioxidant activity owing to the reversible redox cycling between Ce3⁺ and Ce4⁺, enabling them to scavenge excessive reactive oxygen species (ROS) and thereby alleviate lipid peroxidation and inflammation-associated tissue injury. In models of chronic liver injury and hepatic fibrosis, CeO2 NPs have been reported to attenuate hepatic steatosis and inflammation and ameliorate portal hypertension.209 In a rat model of NAFLD induced by a methionine- and choline-deficient diet, CeO2 NPs reduced the size and abundance of lipid droplets in hepatocytes, decreased hepatic levels of fatty acids derived from triglycerides and cholesteryl esters, and modulated cytokine-, adipokine-, and chemokine-related signaling, thereby alleviating hepatic steatosis and inflammation.29 Another study employing models of high-fat diet-induced NAFLD and CCl4-induced liver injury showed that CeO2 NPs enhanced antioxidant capacity in the liver and intestine, reduced TNF-α levels, and attenuated inflammatory tissue injury, further supporting their hepatoprotective effects through antioxidant and anti-inflammatory mechanisms.30 More recently, polydopamine-coated CeO2 nanoparticles (PDA@CeO2) were shown to reduce intracellular ROS levels in hepatic stellate cells, suppress their migration and activation, and decrease the expression of α-SMA and collagen-related markers. In a CCl4-induced liver fibrosis model, PDA@CeO2 attenuated hepatic inflammation, collagen deposition, and tissue fibrosis by modulating the NOX4–TGF-β/Smad3 signaling axis.210 Although this study was not conducted in a MASLD-specific model, oxidative stress, hepatic stellate cell activation, and extracellular matrix deposition are also central events in the progression of advanced MASLD-associated fibrosis. These findings therefore provide mechanistic support for the potential application of this nanosystem in MASLD-related liver fibrosis. In addition, gold nanoparticles, mesoporous silica nanoparticles, and magnetic iron oxide nanoparticles can serve as delivery platforms for small-molecule drugs, nucleic acids, and anti-inflammatory or antifibrotic agents through surface functionalization, loading within mesoporous structures, or magnetic responsiveness.211 For example, in high-fat diet-induced obese mice, gold nanoparticles coated with a long-acting Esculentin-2CHa fusion protein (ESC-ABD-AuNPs) reduced blood glucose levels, improved glucose tolerance, and attenuated hepatic lipid accumulation. These findings suggest that functionalized gold nanoparticles may serve as delivery platforms for bioactive proteins to ameliorate MAFLD-associated metabolic abnormalities.37 Mesoporous silica nanoparticles have also been used to encapsulate salvianolic acid B and provide sustained drug release. By enhancing cellular uptake and bioavailability of the drug in LX-2 hepatic stellate cells, this nanosystem reduced intracellular ROS levels and inhibited cell proliferation, thereby exhibiting potential antioxidant and antifibrotic effects in vitro.212 However, many studies of inorganic nanoparticles have thus far focused primarily on general liver injury, hepatic fibrosis, or imaging models, and their targeting efficiency and therapeutic efficacy in MASLD-specific models require further validation. Inorganic nanoparticles may also be associated with potential risks, including slow biodegradation, long-term retention in the liver and spleen, dose-dependent toxicity, protein corona formation, and immune recognition.213 Therefore, before their application in MASLD therapy, the effects of particle size, morphology, surface charge, and functionalization strategy on hepatosplenic biodistribution, cellular uptake, long-term clearance, and chronic toxicity should be systematically evaluated. It is also essential to distinguish the intrinsic therapeutic effects of the inorganic nanomaterials from the pharmacological effects of their therapeutic payloads. Polymeric Nanoparticles Common materials used for polymeric NPs include PLGA, PEG-PLGA, polycaprolactone, chitosan, hyaluronic acid-modified polymers, and various stimuli-responsive polymers. These NPs exhibit favorable biocompatibility, tunable structures, and broad drug-loading capacity, and their in vivo distribution and cellular uptake can be modulated by adjusting particle size, surface charge, hydrophilicity/hydrophobicity, and ligand modification.214 By tailoring their polymer composition, particle size, surface charge, and degradation properties, and by incorporating targeting moieties such as hyaluronic acid, galactose, glycyrrhetinic acid, vitamin A, or peptide ligands, the hepatic biodistribution, cellular uptake, and payload-release profiles of polymeric nanoparticles can be further optimized. These modifications may also enhance their selectivity toward hepatocytes, activated hepatic stellate cells, or liver macrophages.214,215 Owing to these advantages, polymeric nanoparticles have been widely investigated for the delivery of small-molecule drugs and bioactive antioxidants to regulate MASLD-associated inflammation, lipid metabolic dysfunction, oxidative injury, and cell death. For example, Kurniawan et al encapsulated the spleen tyrosine kinase (SYK) inhibitor R406 in PLGA nanoparticles and demonstrated that the resulting R406-PLGA formulation suppressed M1 macrophage-associated inflammatory markers and ameliorated inflammation, steatosis, and fibrosis in mice with methionine- and choline-deficient diet-induced NASH.52 Hirsch et al encapsulated rimonabant, a centrally active cannabinoid receptor type 1 antagonist, in PLGA nanoparticles to restrict its distribution predominantly to peripheral organs such as the liver. The resulting rimonabant-loaded nanoparticles (Rimo-NPs) enhanced hepatocyte uptake, attenuated hepatic steatosis and liver injury, and improved insulin sensitivity in diet-induced obese mice. Meanwhile, this formulation markedly reduced brain exposure to rimonabant, thereby avoiding the neuropsychiatric adverse effects associated with the free drug.53 Yu et al developed a hepatocyte-targeting polymer composed of 18β-glycyrrhetinic acid, chitooligosaccharide, and N-acetylcysteine for curcumin delivery. The resulting GCNp-Cur nanoparticles targeted glycyrrhetinic acid receptors on the hepatocyte surface, modulated the GPX4/GSH pathway, reduced intracellular labile Fe2⁺ and lipid peroxidation, restored redox and iron homeostasis, and suppressed hepatocyte ferroptosis. These effects ultimately attenuated hepatic lipid accumulation and oxidative injury in NAFLD models.66 Koda et al developed self-assembling poly(ethylene glycol)-block-poly(cysteine) nanoparticles capable of releasing cysteine following degradation by endogenous enzymes. In mouse models of MASH, acyl-protected formulations, particularly nanoparticles containing shorter poly(cysteine) chains, more effectively reduced hepatic lipid accumulation and oxidative stress and subsequently attenuated inflammation and fibrosis.57 Collectively, polymeric nanoparticles can target MASLD through multiple complementary mechanisms, including suppressing macrophage-mediated proinflammatory responses, increasing drug exposure in hepatocytes, improving insulin sensitivity, modulating lipid metabolism, inhibiting ferroptosis, and releasing antioxidant components upon degradation. Nevertheless, their delivery efficiency is influenced by particle size, surface charge, degradation rate, and pathological alterations in the hepatic sinusoidal barrier. Larger nanocarriers may have difficulty traversing the capillarized sinusoidal endothelium and dense extracellular matrix to reach the interstitial space within fibrotic tissues. In addition, the potential toxicity of polymer degradation products and the immune responses associated with long-term administration require further investigation.216 Liposomes Liposomes are classical nanodelivery systems composed of phospholipid bilayers. They exhibit favorable biocompatibility and membrane-fusion capability and can encapsulate both hydrophilic and hydrophobic drugs.217 Because the liver is intrinsically involved in lipid metabolism and lipoprotein processing and is characterized by abundant blood perfusion, a sinusoidal endothelial architecture, and strong uptake capacity by the mononuclear phagocyte system, liposomes and other lipid-based nanodelivery systems possess certain inherent advantages for hepatic drug delivery.218 In MASLD therapy, these delivery systems can improve drug solubility, stability, and intrahepatic exposure, thereby enhancing the in vivo utilization of natural products, antioxidants, anti-inflammatory agents, metabolic modulators, and nucleic acid therapeutics. As a result, they can strengthen therapeutic intervention in key pathological processes such as hepatocellular lipid deposition, inflammatory infiltration, and fibrotic progression.151 For example, natural compounds such as silybin, naringenin, baicalin, and chrysin have antioxidant, anti-inflammatory, and metabolic regulatory potential, but their applications are often limited by poor aqueous solubility, insufficient stability, or low oral bioavailability. Formulating these compounds into liposomes or nanoliposomes can improve delivery efficiency to some extent and reduce hepatic lipid deposition, elevated transaminase levels, inflammatory cell infiltration, and fibrotic responses in NAFLD/NASH animal models.73,219–221 In addition, liposome-based delivery strategies targeting inflammasomes have attracted increasing attention. Negro et al,222 developed anti-FZD1 antibody-modified PEGylated MCC950 liposomes to target inflammation-activated macrophages, which enhanced the inhibitory effect of MCC950 on NLRP3 inflammasome activation in a THP-1 inflammatory model. Hou et al,223 constructed sodium cholate- and mannose-dual-modified sodium acetate liposomes (NaA@SC/MAN-LPs), enabling dual targeting of hepatocytes and Kupffer cells, and improved lipid deposition, liver function injury, macrophage infiltration, and pro-inflammatory responses in NAFLD mice. Although liposomes have a relatively strong foundation for clinical translation, they still face several challenges, including insufficient in vivo stability, clearance by the mononuclear phagocyte system, nonspecific hepatic and splenic accumulation, limited target-cell selectivity, and consistency issues in large-scale manufacturing. Further optimization of particle size, surface charge, lipid composition, and targeting ligand modification is therefore required to improve delivery efficiency and safety.224,225 Bio-Derived Systems Bio-derived nanosystems mainly include extracellular vesicles (EVs) and their exosome subtypes, exosome-like nanovesicles, cell membrane-coated NPs, bacteria-derived vesicles, and lipoprotein-like NPs.226 Among them, EVs are membrane-bound nanovesicles actively released by cells. They can carry bioactive cargoes such as proteins, lipids, mRNAs, miRNAs, and metabolites, and participate in physiological and pathological regulation through intercellular communication.227,228 In MASLD, research on bio-derived systems has mainly focused on EVs/exosomes and their engineered derivatives. EVs are membrane-bound nanovesicles actively secreted by cells and mainly include exosomes, microvesicles, apoptotic bodies, and other subtypes.229 From the perspective of pathological mechanisms, EVs play dual roles in MASLD. On the one hand, EVs derived from lipotoxic hepatocytes, inflammatory macrophages, HSCs, and gut microbiota can act as mediators of intercellular communication and gut–liver axis crosstalk, participating in hepatocyte injury, inflammatory amplification, immune cell recruitment, and fibrotic progression.230–232 On the other hand, reparative EVs, particularly mesenchymal stem cell-derived EVs (MSC-EVs), can exert anti-inflammatory, immunomodulatory, antioxidant, and tissue-repair effects by transferring miRNAs, proteins, and lipid molecules.233,234 Currently, MSC-EVs represent one of the most extensively investigated EV-based therapeutic approaches for MASLD. Preclinical studies have shown that MSC-EVs from different sources can reduce hepatic lipid deposition, improve liver injury markers such as ALT and AST, and alleviate hepatic inflammation and fibrosis in NAFLD/NASH animal models by inhibiting pro-inflammatory cytokine release, modulating macrophage phenotypes, and attenuating HSC activation.235,236 In addition, preclinical systematic reviews and meta-analyses also support the therapeutic potential of MSC-EVs in NAFLD/NASH models. However, current evidence is still mainly derived from animal studies, and high-quality clinical trials in patients with MASLD remain lacking.237 In addition to MSC-EVs, EVs derived from certain endogenous immune cells are also involved in inflammation–fibrosis regulation in MASLD. For example, Hou et al238 found that IL-6 upregulated genes related to exosome biogenesis in myeloid cells and promoted the release of miR-223-enriched exosomes from macrophages. These exosomes transferred miR-223 to hepatocytes and suppressed the expression of the profibrotic transcriptional regulator TAZ, thereby exerting protective effects in the regulation of NAFLD-associated inflammation and fibrosis. Beyond natural EVs and exosomes, exosome-like nanovesicles or exosome-mimetic nanovesicles also provide new engineering strategies for the design of MASLD delivery systems.239,240 These vesicles are generally prepared by cell extrusion, ultrasonication, freeze–thaw cycling, microfluidics, or related methods. They can partially mimic the membrane structure and cellular uptake characteristics of exosomes, while offering higher production yield and greater engineering controllability.241,242 Food-derived exosome-like nanoparticles (FDENs) have also been investigated in preclinical NAFLD/MASLD studies. For example, Zhao et al,106 reported that blueberry-derived exosome-like nanoparticles (BELNs) attenuated mitochondrial oxidative stress in rotenone-treated HepG2 cells and HFD-fed mice, reduced ROS levels, increased mitochondrial membrane potential, and improved the NAFLD phenotype by regulating Nrf2-related antioxidant responses and lipogenesis-related molecules. Zhang et al,112 reported that orally administered broccoli-derived exosome-like nanoparticles (BDENs) reduced hepatic lipid deposition and liver injury in HFD-induced MASLD mice. These effects were associated with improvement of the intestinal barrier, modulation of gut microbiota and bile acid metabolism, reduced LPS translocation, and attenuation of hepatic inflammatory responses, suggesting gut–liver axis-related protection. Collectively, these studies suggest that FDENs may provide new preclinical intervention strategies for oxidative stress, dysregulated lipid metabolism, and gut–liver axis abnormalities in MASLD. However, their active components in vivo, target cell populations, dose standardization, and long-term safety require further validation. Potential Applications of Virus-Like Particles in MASLD Therapy Virus-like particles (VLPs) are nanoscale structures formed through the self-assembly of one or more viral structural or capsid proteins. Because they lack a complete replication-competent viral genome, VLPs are generally nonreplicative and noninfectious, while retaining, to some extent, the highly ordered structural features and cellular uptake capacity of native viruses.243,244 VLPs typically exhibit relatively uniform particle sizes, tunable internal cavities, and multivalent surface-display capabilities. Their internal cavities can accommodate nucleic acids, proteins, small-molecule drugs, or gene-editing ribonucleoprotein complexes, whereas their external surfaces can be functionalized with cell-targeting ligands through genetic engineering or chemical conjugation.245,246 The potential of VLPs for liver-targeted delivery has been preliminarily demonstrated in several hepatocyte-related experimental systems. L particles formed from the hepatitis B virus large envelope protein have been used to deliver reporter genes, protein-coding genes, and imaging tracers to human hepatocytes and have shown preferential distribution within human liver-derived tissues in mouse xenograft models of human hepatocellular carcinoma.246 In addition, cell-penetrating VLPs derived from the hepatitis B virus nucleocapsid have enabled the delivery of exogenous genes to primary human hepatocytes.247 Engineered hepatitis E VLPs can also encapsulate exogenous plasmids and have demonstrated efficient cellular uptake and gene delivery in liver-derived cells and rat liver tissues.248 Collectively, these studies suggest that VLPs derived from hepatotropic viruses may retain a certain degree of tropism toward hepatic tissues or hepatocytes. In addition to exploiting their intrinsic tissue tropism, VLPs can be modified with surface ligands to achieve receptor-mediated hepatocyte targeting. For example, multivalent display of ligands for the asialoglycoprotein receptor (ASGPR) on the VLP surface can promote particle internalization by ASGPR-expressing cells, with uptake efficiency jointly determined by ligand affinity and surface-display density.249 Because ASGPR is highly expressed on hepatocytes, this strategy provides a feasible engineering approach for delivering therapeutic payloads to these cells. Engineered VLPs may also be used for the transient delivery of gene-editing cargoes. For example, DNA-free engineered VLPs have been used to package and deliver Cas9 or base-editor ribonucleoprotein complexes, thereby enabling transient gene-editing activity in vivo.250 Subsequently developed prime editor-engineered VLPs can simultaneously deliver prime editor proteins, prime-editing guide RNAs, and auxiliary guide RNAs.251 Furthermore, VLP platforms with programmable cellular tropism have demonstrated the potential to tailor delivery specificity according to the target cell type.252 In the context of MASLD, direct evidence that VLPs can ameliorate hepatic steatosis, inflammation, hepatocellular injury, or fibrosis in animal models or patients is currently lacking. Their application in MASLD therefore remains a prospective strategy extrapolated from studies of liver targeting and therapeutic cargo delivery. Future studies could investigate hepatocyte-targeted VLPs for delivering siRNAs, mRNAs, therapeutic proteins, or gene-editing complexes to modulate fatty acid uptake, de novo lipogenesis, oxidative stress, inflammatory signaling, and fibrosis-related pathways. Surface engineering of VLPs to target hepatic stellate cells, Kupffer cells, or other hepatic nonparenchymal cells may also offer new opportunities to regulate the multicellular interactions involved in MASLD progression. Nevertheless, the translation of VLPs into MASLD therapy faces several challenges, including viral capsid-associated immunogenicity and pre-existing immunity, the stability of intrinsic or engineered tissue tropism, clearance by the mononuclear phagocyte system, limited cargo-encapsulation efficiency, inadequate endosomal escape and intracellular cargo release, interference of complex payloads with particle assembly, batch-to-batch variability, and the safety of repeated administration. Because MASLD generally requires long-term or repeated treatment, whether VLPs can maintain their targeting efficiency while avoiding substantial immune responses following repeated administration must be systematically evaluated in disease-relevant animal models. At present, VLPs should therefore be regarded as a potential complementary platform for precision nanotherapy of MASLD rather than an established or clinically mature therapeutic strategy. Comparative Assessment and Selection Criteria for Nanoplatforms in MASLD Therapy The major nanoplatforms discussed above should not be regarded as interchangeable delivery tools, because their suitability depends on the therapeutic payload, intended hepatic cell population, disease stage, anticipated treatment duration, and required mechanism of action. Inorganic nanoparticles exhibit high structural stability and may possess intrinsic optical, magnetic, or redox properties, giving them considerable potential for imaging and theranostic applications. However, MASLD is a chronic metabolic disease that generally requires long-term treatment. The slow degradation of inorganic nanoparticles, their potential long-term retention in the liver and spleen, and the associated risk of chronic toxicity may therefore limit repeated administration. Accordingly, inorganic nanoparticles may offer greater value when the carrier itself provides therapeutic or diagnostic functionality. When they serve solely as long-term drug-delivery vehicles, their necessity and benefit–risk profile require more careful evaluation. Polymeric nanoparticles offer substantial flexibility in material composition, ligand conjugation, payload loading, and controlled or stimuli-responsive release. These characteristics make them particularly suitable for delivering small-molecule drugs, antioxidants, and nucleic acid therapeutics that require sustained release or release in response to pathological microenvironmental cues. Nevertheless, polymer degradation behavior, physicochemical stability, manufacturing reproducibility, and the ability to traverse capillarized hepatic sinusoids and the fibrotic extracellular matrix remain important considerations. Complex polymeric nanoparticle designs are therefore justified only when controlled release or modular surface engineering provides a clear therapeutic advantage over simpler formulations. Among the platforms discussed in this review, liposomes and lipid nanoparticles currently have a relatively mature foundation for clinical translation, particularly for the hepatic delivery of small-molecule drugs and nucleic acid therapeutics. Modulation of lipid composition can improve payload encapsulation, endosomal escape, and pharmacokinetic behavior. However, overall hepatic accumulation does not necessarily indicate selective delivery to hepatocytes or other therapeutically relevant hepatic cell populations, because a substantial proportion of nanoparticles may be taken up by Kupffer cells and other components of the mononuclear phagocyte system. Lipid-based nanosystems are therefore particularly well suited for nucleic acid delivery, but their cell-type selectivity requires further optimization when therapeutic efficacy depends on precise targeting of hepatocytes, macrophages, liver sinusoidal endothelial cells, or hepatic stellate cells. Bio-derived and biomimetic nanosystems contain natural membrane components and possess features associated with intercellular communication, which may facilitate biological recognition, multicellular regulation, or oral modulation of the gut–liver axis. Nevertheless, a biological origin does not necessarily ensure greater safety or reproducibility. Source-dependent heterogeneity, incompletely characterized endogenous cargoes, limited loading efficiency, challenges in large-scale purification, inadequate storage stability, and batch-to-batch variability remain major barriers to clinical translation. Similarly, VLPs offer relatively uniform structures, multivalent ligand-display capacity, and the ability to deliver protein or nucleic acid cargoes. However, their application in MASLD remains largely prospective because direct disease-specific evidence is limited, while capsid-associated immunogenicity and pre-existing immunity may compromise the safety and efficacy of repeated administration. Overall, no single nanoplatform is universally optimal for all therapeutic applications in MASLD. Platform selection should therefore follow a fit-for-purpose principle. Lipid-based nanosystems may be particularly suitable for hepatocyte-targeted nucleic acid delivery, whereas biodegradable polymeric systems may offer advantages when sustained or stimuli-responsive release is required. Ligand-functionalized lipid or polymeric carriers may be more appropriate for targeting activated hepatic stellate cells or other nonparenchymal cell populations, whereas bio-derived systems may be better suited for modulating multicellular communication or the gut–liver axis. In advanced liver fibrosis, carrier size, deformability, and the ability to penetrate the extracellular matrix may be more important than overall hepatic accumulation. Rational nanoplatform design should therefore align the carrier with the therapeutic payload, target cell population, pathological barriers, disease stage, and anticipated treatment duration, rather than increasing structural complexity in the absence of a clearly defined therapeutic benefit. Discussion MASLD is not merely hepatic fat accumulation caused by a single metabolic abnormality; rather, it is a chronic progressive disease jointly driven by dysregulated lipid metabolism, insulin resistance, oxidative stress, inflammatory responses, gut–liver axis abnormalities, and fibrotic remodeling.122,253 This multifactorial pathological nature determines that interventions targeting a single molecule or pathway are often insufficient to cover the entire course of disease progression. Conventional free drugs are also frequently limited by poor aqueous solubility, insufficient in vivo stability, limited effective intrahepatic exposure, and weak target-cell selectivity, which may compromise their sustained activity in diseased liver tissue. Nanodelivery systems can improve the in vivo distribution of therapeutics by modulating particle size, surface charge, material composition, release behavior, and ligand modification, thereby enhancing their accumulation in the liver and specific hepatic cell populations.25,151,254 Current evidence indicates that nanodelivery strategies for MASLD have gradually shifted from simply improving drug solubility toward designs based on specific pathological processes and cellular targets. For lipid deposition, oxidative stress, inflammation, insulin resistance, and fibrosis, nanosystems can be used to deliver lipid-lowering agents, antioxidants, nucleic acid therapeutics, anti-inflammatory molecules, and antifibrotic payloads, respectively.151,255,256 Meanwhile, hepatocytes, Kupffer cells/monocyte-derived macrophages, HSCs, and LSECs play distinct roles in MASLD progression.257,258 Therefore, the key to targeted delivery is not merely whether therapeutics enter the liver, but whether they are delivered to the appropriate cell type. Different nanoplatforms have their own advantages and limitations in MASLD therapy. Inorganic NPs have potential in oxidative stress regulation, imaging, and theranostics, but long-term accumulation and chronic toxicity remain important limitations for their application in chronic metabolic diseases.259 Polymeric NPs exhibit favorable structural tunability, drug-loading capacity, and controlled-release properties, making them suitable for delivering small-molecule drugs and nucleic acid therapeutics. However, their in vivo degradation, particle size stability, and penetration into fibrotic tissues require further evaluation.260 Liposomal formulations have a relatively mature technological and translational foundation and can improve the solubility, stability, and intrahepatic exposure of natural products, anti-inflammatory agents, and metabolic modulators. Nevertheless, they still face challenges such as clearance by the mononuclear phagocyte system, nonspecific accumulation in the liver and spleen, and batch-to-batch consistency.217 Bio-derived nanosystems, such as EVs, MSC-EVs, and FDENs, possess natural membrane structures and cell-communication features and show unique advantages in multicellular regulation and targeted delivery. However, source heterogeneity, complex cargo composition, quality control, and long-term safety remain key issues that must be addressed before further translation.226,227,261 Notably, some nanotherapeutic strategies have begun to show clinical translational potential. For example, Yu et al,262 first identified elevated ceramide levels in human MASLD/MASH samples and confirmed the upregulation of SPTLC2 expression in hepatocytes. They then employed a clinically validated LNP platform similar to that used in the approved siRNA drug Onpattro to deliver SPTLC2 siRNA to hepatocytes, thereby selectively inhibiting de novo hepatic ceramide synthesis. This strategy not only reduced hepatic and circulating ceramide levels but also alleviated hepatic steatosis, inflammation, and fibrosis in MCD diet- and long-term CD-HFD-induced MASH mouse models, suggesting that hepatocyte-targeted LNP-siRNA delivery may represent a promising translational approach for precise metabolic intervention in MASLD/MASH. In addition, BMS-986263, a retinol-conjugated lipid nanoparticle, can deliver siRNA targeting HSP47 to suppress the expression of the collagen-specific molecular chaperone HSP47 and reduce ECM deposition. This agent has entered clinical studies in patients with advanced liver fibrosis and has shown preliminary evidence of safety, target engagement, and antifibrotic translational potential.263,264 These studies indicate that the design of MASLD nanotherapeutics is evolving from merely improving drug solubility and intrahepatic exposure toward precise delivery targeting specific hepatic cell types, key metabolic pathways, and fibrogenic processes. However, most nanotherapeutic strategies for MASLD remain at the cellular or animal study stage, and only a limited number of related formulations have entered clinical evaluation. Nanodelivery systems have therefore not yet become established clinical treatments for MASLD/MASH. In contrast, resmetirom, an oral, liver-directed thyroid hormone receptor-β agonist, has been approved for the treatment of adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.12 Compared with approved small-molecule drugs such as resmetirom, nanodelivery systems may offer potential advantages by improving delivery to specific hepatic cell populations, increasing the effective intrahepatic exposure of therapeutic payloads, enabling the delivery of nucleic acid therapeutics, and facilitating combination therapies that simultaneously target multiple pathological pathways.50,58 However, these proposed advantages are currently supported mainly by theoretical considerations and preclinical evidence and have not been adequately validated in human studies. This translational gap is closely related to limitations in the current evidence base. Commonly used experimental models differ from human MASLD in terms of metabolic background, disease duration, fibrosis progression, immune microenvironment, and comorbidity profiles. Consequently, favorable results obtained in short-term or nutrient-deficient models may not adequately predict the efficacy and safety of the corresponding nanoformulations in patients with chronic metabolic disease. Moreover, substantial heterogeneity among studies in nanomaterial composition, particle size, surface properties, therapeutic payloads, administration routes, doses, treatment durations, and efficacy endpoints complicates cross-study comparisons and evidence synthesis. Systematic comparative studies of different nanoplatforms remain scarce, and the available evidence is insufficient to establish the general superiority of any single platform for MASLD treatment. Instead, the suitability of a given platform is more likely to depend on the therapeutic payload, target cell population, disease stage, and dosing requirements. Importantly, increased overall hepatic accumulation of a nanocarrier does not necessarily indicate effective delivery to the intended target cells. Some nanocarriers may be sequestered by the mononuclear phagocyte system, retained within the hepatic sinusoidal compartment, or distributed to intrahepatic cells and tissue regions that are only weakly associated with the intended therapeutic effect. Delivery performance should therefore be evaluated not only on the basis of total hepatic accumulation but also by determining the actual distribution, uptake efficiency, and effective payload release across different hepatic cell populations. Future studies should prioritize chronic and metabolically relevant models that more closely recapitulate human MASLD and should characterize nanocarrier biodistribution, cellular uptake, tissue penetration, intracellular trafficking, and clearance at different disease stages. Particular attention should be given to the effects of LSEC capillarization, extracellular matrix accumulation, and altered hepatic immune function on delivery efficiency. Nanoplatform selection should be guided by the intended therapeutic purpose, with integrated consideration of the therapeutic payload, target cell population, pathological barriers, disease stage, and anticipated treatment duration. For example, lipid-based nanosystems may be particularly suitable for hepatic nucleic acid delivery, whereas polymeric nanoparticles may be better suited to sustained or pathological microenvironment-responsive release. The advantages of inorganic nanoparticles may lie primarily in their intrinsic redox, magnetic, or imaging properties, while bio-derived systems may be more applicable to the modulation of intercellular communication or gut–liver axis interventions. Nevertheless, these potential differences in platform suitability require validation through standardized head-to-head comparative studies. Long-term and repeated-dose studies are also required to systematically assess nanocarrier toxicity, off-target accumulation, immunogenicity, and the reversibility of tissue retention. Standardized physicochemical characterization, reproducible manufacturing processes, scalable production, batch-to-batch consistency, and clinically relevant efficacy endpoints should be incorporated from the early stages of nanoplatform development. Finally, direct comparisons should be conducted under the same disease models and experimental conditions among free drugs, non-targeted nanocarriers, actively targeted systems, different classes of nanoplatforms, and existing pharmacological treatments such as resmetirom. Greater structural and functional complexity should not automatically be regarded as a therapeutic advantage. The development of complex nanosystems is justified only when this complexity produces reproducible and clinically meaningful improvements in efficacy, safety, target-cell exposure, dosing frequency, or therapeutic applicability. Conclusion Nanodelivery systems provide a promising approach for MASLD treatment by improving therapeutic stability and intrahepatic exposure and enabling mechanism-oriented and cell-specific intervention. Current evidence suggests that inorganic, polymeric, lipid-based, and bio-derived nanosystems can regulate multiple pathological processes involved in MASLD, including lipid metabolic dysfunction, oxidative injury, inflammation, insulin resistance, gut–liver axis abnormalities, and fibrosis. Recent studies have increasingly focused on targeted delivery to hepatocytes, liver macrophages, HSCs, and LSECs, as well as nucleic acid delivery and pathological microenvironment-responsive release. However, most studies remain at the cellular or animal level, and the clinical relevance of these findings requires further validation. Only a limited number of related formulations, such as BMS-986263, have progressed to clinical evaluation, and nanodelivery systems have not yet become established treatments for MASLD/MASH. In contrast, resmetirom has been approved for adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis, highlighting the need for future nanotherapies to demonstrate clinically meaningful added value over existing treatments. Future studies should place greater emphasis on chronic and metabolically relevant disease models, the intrahepatic distribution and long-term clearance of nanocarriers, repeated-dose safety, and direct comparisons with free drugs or non-targeted formulations. Manufacturing reproducibility, batch-to-batch consistency, and standardized quality control should also be considered during the early stages of nanoplatform development. The potential value of nanodelivery systems lies not only in increasing hepatic drug accumulation, but also in improving delivery to specific hepatic cell populations and supporting the use of nucleic acid therapeutics or combination treatments. Further evidence from clinically relevant models and well-controlled translational studies will be required to determine whether these advantages translate into meaningful improvements in MASLD treatment. Acknowledgments The authors acknowledge the use of BioRender (https://app.biorender.com/) in creating the schematic illustrations presented in this manuscript (Figures 1–4). Funding Statement The present study was financially supported by the National Natural Science Foundation of China (No. 82575017), Sichuan Provincial Administration of Traditional Chinese Medicine Major Science and Technology projects (2021XYCZ004). Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Na Li and Dongqi Zhou should be considered co-first authors. Disclosure The authors declare that no commercial or financial relationships exist that could be interpreted as potential conflicts of interest in relation to this research. References